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1 Introduction 
The main subject of this work was the synthesis of stable calcium phosphate 
colloids, their characterization and examination on cells.  
The non-viral transfer of DNA into cells is called transfection. The main 
problem of non-viral transfection methods is their low efficiency, e.g. a low 
uptake of DNA by the cells and low gene expression. Because of that it is 
necessary to develop an appropriate drug delivery system which can protect 
DNA and RNA from the degradation by nucleases and successfully deliver it 
into the nucleus. 
To study the interaction between organic and inorganic molecules in order to 
understand the mechanism of uptake and pathway of nanoparticles inside the 
cells is a great challenge in gene therapy, therefore, the cooperation with other 
fields of science such as colloid and physical chemistry or biochemistry was 
necessary. In the cooperation with Max-Planck-Institute of Colloids and 
Interfaces and with the University of Dortmund, department of physical 
chemistry, the main characteristics of calcium phosphate colloids and the 
developing of monodisperse ones for the biological application were 
accomplished. In the cooperation with the University of Bochum, chair of 
biochemistry, and with the institute of physico-chemical biology in Moscow the 
influence of physical parameters of the colloids, such as particle size, charge 
and stability, on the transfection efficiency and gene silencing were shown. 
The aim of the work was to create a delivery system not only for DNA and 
RNA, but also for oligonucleotides which are used for down-regulation of gene 
expression by targeting the mRNA, resulting in effective gene silencing. 
The open question in non-viral gene therapy is the understanding of all 
extracellular and intracellular physico-chemical barriers which DNA has to 
overcome for a successful incorporation into the nucleus. For this purpose it was 
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necessary to follow the pathway of nanoparticles into the cell by laser confocal 
microscopy.  
The last topic was to develop a method for the preparation of ubiquitin-loaded 
calcium phosphate materials. Ubiquitin has very similar adsorption properties 
like rhBMP-2, which leads to enhanced bone growth and can be used as a model 
protein for the experiments. Understanding the interaction between calcium 
phosphate and ubiquitin can help to develop long-term implants for successful 
osseointegration.   
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2 Theoretical background 
2.1 Nanoparticles and Nanotechnology 
Nanotechnology comprises technological developments at scales less than 100 
nm. The technology stretches across the whole spectrum of science, touching 
medicine, physics, engineering, and chemistry.  
Nanoparticles are distinguished from the bulk phase by their high surface-to-
volume ratio which causes their specific optic, electronic and catalytic 
properties.  
Semiconducting nanoparticles, e.g. CdS or CdSe, are used for light-emitting 
applications in telecommunication systems. TiO2 , ZnO and Ta2O5 nanoparticles 
are used in solar cells[1, 2], TiO2 and ZnO nanoparticles find in addition a 
comparatively "trivial" application as pigments in dye and lacquers. 
Nanoparticles of TiO2 are also used in sun screen lotions, because they absorb 
UV light[3]. 
Great attention is paid to ferromagnetic nanoparticles[4] due to their potential 
application in computer technologies and medicine, where they are used for 
magnetic hyperthermia to destroy cancerous tissue with heating.  
Bio-oriented nanotechnology research is focused on main directions like 
developing fluorescent markers using semiconducting nanoparticles, 
biomolecule detection and drug delivery[5]. 
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2.1.1 Colloids 
A colloid is a system which consists of a dispersed phase finely divided and 
distributed throughout dispersion medium. The dimensions of the disperse phase 
lie in the range of 1 nm to 1 µm. Colloidal systems have large ratio of surface 
area to volume of the dispersed particles.  
Colloidal system have been known and exploited by mankind for centuries in 
areas ranging from pigments and paints to medicines, photography, agriculture 
and others[6].  
There are various combinations of gas, liquid, and solid as dispersed phase or as 
continuous medium in disperse systems. Familiar colloidal systems are the 
following: fog, smoke, milk and glass (Table 2.1.1.1). 
 
Table 2.1.1.1: Examples of two-phase colloidal systems 
 
Dispersed phase Dispersion 
medium 
Name Examples 
liquid gas liquid aerosol fog, liquid spray, mist 
solid gas solid aerosol smoke, dust 
gas liquid foam soap foam 
liquid liquid emulsion milk, mayonnaise 
solid liquid sol, suspension gold sol, paste, gel 
gas solid solid foam expanded polystyrene 
solid solid solid suspension alloy, pigmented plastics 
 
Many biological systems, including cell membrane formation, certain digestive 
processes and blood transport phenomena, involve various forms of associated 
colloidal structures[7]. 
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2.1.2 The electrical double layer 
At any surface there is always an uneven distribution of electrical charges 
between the two phases. The particles in a colloid are almost always electrically 
charged. This charge on the particle is balanced by an opposite charge in the 
surrounding fluid. The charge in the fluid is in the form of ions. Ions in 
immediate contact with the surface are located in the Stern layer. Ions farther 
away from the surface form a diffuse layer (Figure 2.1.2.1). The electrical 
double layer exists at the solid-liquid interface. 
The zeta potential is the difference in electrical potential between the dense layer 
of ions surrounding the particle and the bulk of the suspended fluid. 
When ions or polymers are adsorbed on a particle in a colloidal system, or by 
the dispersed liquid in an emulsion, the charge of the layer surrounding the 
particle is changed. This results in a change in the potential difference between 
the surrounding layer of ions and the bulk of the suspending fluid. This is a 
change in the zeta potential. The stability of a colloidal system is dependent on 
the degree of ion adsorption, and, therefore, on the zeta potential. Zeta potential 
measurements make it possible to control the process of dispersion or 
agglomeration. 
All aqueous colloids have a negative or positive charge. The stability of the 
system is increased when the zeta potential exceeds ± 30 mV generally represent 
sufficient mutual repulsion to result in stability. This can be accomplished by the 
addition of an anionic electrolyte or polyelectrolyte. Stability is assured within a 
zeta potential range of ± 45 to ± 70 mV. 
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Figure 2.1.2.1: Schematic representation of the electrical double layer. 
 
When agglomeration is desired, it is necessary to bring the zeta potential closer 
to zero. This can be achieved by the addition of polyelectrolytes. 
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2.1.3 Colloid stability and DLVO theory 
A colloidal dispersion may be stable or unstable towards aggregation. A stable 
colloidal system is one in which the particles resist flocculation or aggregation. 
This will depend upon the balance of the repulsive and attractive forces that 
exist between particles as they approach each other.  
B
C D
A
 
 Figure 2.1.3.1: Illustration of four possible forms of the total free energy (iii), resulting 
from the combination of attractive (i) and repulsive (ii) combinations[8]. 
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The DLVO theory (developed by Derjaguin, Landau, Verwey and Overbeek)[9, 
10] proposes that the stability of a particle in solution depends on the total 
interaction energy, which is the sum of the attractive van der Waals force and 
the repulsive force that arise when the diffuse double layer round the two 
particles overlap[11] (Figure 2.1.3.1). 
In Figure 2.1.3.1 is shown the interaction-free energy ∆G as a function of the 
distance (H) between the particles. The total free energy (iii) is the sum of the 
attractive (i) and repulsive (ii) energy. Diagram A on the Figure 2.1.3.1 shows 
states of separation and contact separated by a high energy barrier (primary 
maximum P) arising from strong repulsive interaction. This colloidal dispersion 
is stable. If conditions are adjusted so that the energy barrier becomes negligibly 
small by reduction of repulsive interactions or decrease in their range, the 
system will be able to pass over into the primary minimum M1 and then the 
colloid becomes unstable (Figure 2.1.3.1 B). By elimination of the energy 
barrier, the system will be able to pass over into the primary minimum M1 
without any activation energy (Figure 2.1.3.1 C). On the Diagram C the 
existence of the secondary minimum M2 is shown. In this situation flocculation 
may occur. An important feature of such a situation is that although the 
agglomerates are sufficiently stable to be not completely dissociated by 
Brownian motion, they may disintegrate under externally applied hydrodynamic 
forces. 
 
 
2.1.4 Aging and coagulation of colloids 
The aging process is the tendency of the dispersion to achieve a 
thermodynamically stable state. The solubility of each substance depends on the 
particle size. Small particles have a higher solubility than large particles. 
The aging speed dm/dt is given by: 
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The aging speed depends on the concentration of the macroscopic phase (co), the 
surface tension (γ), the particle radius (r1; r2), the diffusion coefficient (D), the 
temperature (T) and the viscosity (δ). 
 
According to the equation, monodisperse colloidal systems should not age. 
However, it is difficult to prepare really monodisperse colloids. Monodisperse 
colloids age substantially more slowly. Aging can be accelerated by increasing 
the temperature because the solubility and the diffusion coefficient are 
increasing with increasing temperature. Aging is the natural, spontaneous and 
slowly occurring process of the destruction of a colloidal dispersion. At the end 
of this process, the separated solid phase and the dispersion medium are present. 
Increasing temperature promotes the coagulation, because it strengthens the 
Brownian motion of the particles. In consequence of the coagulation, colloidal 
particles assemble to larger aggregates. 
Under these conditions the coagulation is also called agglomeration. The 
assembled particles in the agglomerates initially keep their original size and 
shape. Then, in a subsequent process, recrystallisation occurs. If such features 
arise, then the coagulation will be irreversible and can not go backwards to a 
redispersion. 
The final state of the coagulation process is a coagulate, which usually possesses 
the structure of a gel, which is also called lyogel or xerogel. The gel structure 
depends on the structure of colloidal particles and the solvatation conditions. We 
differentiate between reversible and irreversible coagulations. 
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2.1.5 Stabilization of colloidal systems 
In general, there are two mechanisms for stabilization of colloids: electrostatic 
repulsion between the electrical double layer and steric stabilization. The 
electrostatic stabilization was discussed above.  
The steric stabilizing mechanism includes the adsorption of polymeric protective 
agents or steric stabilizers on the particle surface. Such molecules do not have to 
carry an electrical charge but must have a relatively low solubility in the 
dispersion medium and a high tendency to adsorb onto the particle surface, 
which results in the formation of an adsorbed layer and improves the stability of 
the colloid by the imposition of a barrier to close particle approach. 
The calcium phosphate colloids in the presence of DNA or proteins involve a 
combination of both electrostatic and steric stabilization mechanisms. DNA and 
proteins in this case are excellent protective agents. DNA, for example, is a 
biopolymer and provides good steric stabilization and because of its negative 
charge, DNA provides electrostatic stabilization as well. 
 
 
2.1.6 Calcium phosphate  
Calcium phosphates are a very important inorganic component of biological 
hard tissues. They are present in bone, teeth, and tendons in form of carbonated 
hydroxyapatite (HA) to give stability, hardness, and function of these organs. 
Calcium phosphate crystals are also found in the nature as mineral deposits of 
considerable size, having grown over many years under sometimes extreme 
conditions of pressure and temperature. Biologically formed calcium phosphates 
that are precipitated under mild conditions (ambient pressure, near room 
temperature) are often nanocrystals. 
Calcium phosphates are of great interest in medicine, biology and materials 
sciences[12]. Due to their biocompatibility, they are used as bone substitution 
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materials. In addition, calcium phosphate nanoparticles are used as non-viral 
DNA delivery system in cell biology. 
The existence of various calcium phosphate salts of ortho-phosphoric acid can 
be explained by the combination of calcium with three protolysis steps of 
phosphoric acid: 
 
H3PO4 + H2O → H3O+ + H2PO4−  pK1 = 2.16 
H2PO4− + H2O → H3O+ + HPO42−  pK2 = 7.21 
HPO42− + H2O → H3O+ + PO43−  pK3 = 12.33 
 
All calcium phosphate in pure state are white solid bodies and the most of them 
are just a little soluble in water, but all calcium phosphate are soluble under 
acidic conditions. A variety of stoichiometric calcium phosphates is known, but 
we will discuss only those which are of interest here: ACP (amorphous calcium 
phosphate) and HA (hydroxyapatite). 
ACP is often encountered as a transient phase during the formation of calcium 
phosphates in aqueous systems. ACP is the first phase that is precipitated from a 
supersaturated solution prepared by rapid mixing of solutions containing of 
calcium cations and phosphate anions[13-17]. The solution pH value and the 
concentrations of calcium and phosphate ions in the mother liquor have a strong 
influence on the chemical composition of ACP. Electron microscopy of ACP 
usually reveals spherical particles with typical diameters of 20-200 nm and X-
ray diffraction experiments show the amorphous state. IR spectra of ACP show 
broad, featureless phosphate absorption bands. In medicine, ACP is sometimes 
used in calcium phosphate cements[18-20].  
HA (Ca10(PO4)6(OH)2) is the most stable and least soluble of all calcium 
orthophosphates. HA can be prepared in aqueous solutions by mixing exactly 
stoichiometric quantities of calcium- and phosphate-containing solutions at 
pH>9, followed by boiling for several days under a CO2-free atmosphere, 
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filtration, and drying. In HA calcium ions may be partially replaced by Sr, Ba, 
Mg, K, Na, Fe, phosphate ions may be replaced by AsO43-, CO32-, and VO43- and 
hydroxide ions may be replaced by F-, CO32- and Cl-. 
Pure HA never occurs in biological systems. However, because of the chemical 
similarities to bone and teeth mineral, HA is widely used as a coating for 
orthopedic and dental implants, and a calcium phosphate cement with HA has 
also been developed[21]. Because of the great similarity to bone mineral, HA is 
also used as solid phase in liquid chromatography of proteins and other 
biological compounds[22-26]. 
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2.2 Biopolymers applied for the stabilization of calcium phosphate 
colloids 
2.2.1 Desoxyribonucleic acid (DNA) 
Desoxyribonucleic acid (DNA) is the molecular carrier of the hereditary 
information. This term does not describe a certain molecule, but rather a 
molecule class, which occurs in different variants in the nucleus and in the 
organelles of the individual cells. DNA is a linear polymer composed of 
monomers, called desoxynucleotides. All nucleotides consist of three 
components: A purine (adenine or guanine) or a pyrimidine (cytosine or 
thymine), a desoxyribose and a phosphate moiety. 
 
Adenine (A)
Thymine (T)
Guanine (G)
Cytosine (C)
Hydrogen bond
Hydrogen bond
 
 
Figure 2.2.1.1: The chemical structures of purine (adenine and guanine) and pyrimidine 
(cytosine and thymine) bases in desoxyribonucleic acids. 
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A phosphate group is linked by a phosphoester bound to a desoxyribose which is 
linked to an organic base. The links between the nucleotides are called 
phosphodiester bonds. Therefore each chain has a 5' and 3' end, where the 5' end 
is shown as a start and the 3' end as an end. 
O
CHHC
HC CH
O
CHHC
HC CH
O
CHHC
HC CH
O
HC CH
CHHC
O
HC CH
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HC CH
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H O
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H O
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O H
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T A
CH2
CH2
CH2
CH2
CH2
 
Figure 2.2.1.2: Representation of contacts within the DNA double helix. 
 
Nucleotides are complementary to each other, i.e. purines (A, G) are paired with 
pyrimidines (C, T) (Figure 2.2.1.1). The complementary pairs of nucleotides 
adenine (A) and thymine (T) are stabilized by two hydrogen bonds. On the other 
hand the complementary pair of nucleotides guanine (G) and cytosine (C) has 
three hydrogen bonds, so that this structure is more stable than between A and T, 
and it can explain the higher melting temperature for G/C-rich DNA double 
helix at which the strands of DNA will separate. 
Complementary nucleic acid strands are always antiparallel, that is their 5' → 3' 
directions are opposite (Figure 2.2.1.2)[27, 28].  
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2.2.2 Ribonucleic acid (RNA) 
Beside the DNA there are also other nucleic acids: ribonucleic acid (RNA). In 
RNA, the pentose is ribose, and instead of thymine presented in DNA, uracil is 
present in RNA (Figure 2.2.2.1). 
Fundamentally, RNA can be divided into three functional groups: 
1. Ribosomal RNA (rRNA) is a component of the ribosomes, the protein 
synthetic factories in the cell. 
2. Transfer RNA (tRNA) transfers a specific amino acid to a growing 
polypeptide chain at the ribosomal site of protein synthesis during 
translation. 
3. Messenger RNA (mRNA) is RNA that encodes and carries information 
from DNA during transcription to sites of protein synthesis to undergo 
translation[27, 28]. 
 
O
O
C
CC
C
N
N
H
HH
HO
O
OH
H2
H
HH HH
OH
C
C
C
C
C OH
Ribose Uracil (U)
 
 
Figure 2.2.2.1: The chemical structures of ribose and uracil in ribonucleic acids. 
 
2.2.3 Oligonucleotides 
An oligonucleotide is a molecule which is formed by several nucleotides (DNA 
or RNA). Its sequence consists of approximately 10-30 nucleotides. 
In 1978 Stephenson et al. published the specific inhibition of Rous sarcoma viral 
RNA translation by a specific oligonucleotides[29, 30]. This was the start of a large 
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amount of research work in the field of oligonucleotides, in order to make these 
accessible for a pharmacotherapy. 
Oligonucleotides as potential pharmaceutics are short, single-stranded DNA and 
single-stranded or double-stranded RNA. Such oligonucleotides are usually 
obtained by solid phase syntheses[31]. 
 
 
2.2.4 Proteins 
2.2.4.1 Protamine 
Protamine is a highly cationic peptide (due to the presence of 21 arginine 
residues) with a molecular weight around 4000-10000 Da and an average 
number of approximately 30-35 amino acids per molecule[32].  
During spermatogenesis, nuclear histones are gradually replaced by new 
synthesized sperm-specific protamine[33]. Histones are located in somatic 
cells[34], however protamine are found exclusively in sperm cells. Protamine 
binds to DNA and causes a compact packing of the hereditary information in the 
sperm cells, thereby protecting chromosomal DNA from degradation. 
Protamine contains four nucleic localization sequences (NLS), which help DNA 
in the overcoming of the nuclear membrane barrier. This is an important factor 
for later developments of delivery systems for DNA and oligonucleotides[35-37]. 
Protamine sulfate can induce higher levels of gene expression than poly-L-lysine 
and other types of protamines when combined with DNA[38, 39]. 
2.2.4.2 Bovine serum albumin (BSA)  
Bovine serum albumin (BSA) is one of the most widely studied proteins. It 
belongs to the class of serum proteins called albumins, which make up about 
half of the protein in plasma and are the most stable and soluble proteins in 
plasma (Figure 2.2.4.2). The molecular weight of BSA is 67000 Da[40]. It is a 
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popular delivery system for weakly antigenic compounds. BSA serves as 
delivery system for DNA and oligonucleotides into cells[37, 41]. 
 
 
Figure 2.2.4.2: Structure of human serum albumine (from protein data base). The structure 
has seven molecules of arachidonic acid bound to it. The protein is shown with lines and the 
fatty acids are shown with spheres at each atom. Arachidonic acid is an unsaturated fatty acid 
with several double bonds that form rigid kinks in the carbon chain. 
 
2.2.4.3 Ubiquitin 
Ubiquitin contains 76 amino acids with a molecular weight of approximately 
8500 Da. This protein is found both as free monomer in eukaryotic cells, and 
covalently attached to other proteins[42, 43]. 
Nuclear magnetic resonance (NMR) and chemical studies showed that ubiquitin 
is a compact, globular protein (Figure 2.2.4.3)[44]. 
Ubiquitin has different functions. On the one hand it serves as a marker to the 
marking of proteins which have to be destroyed. The protein which has to be 
removed is covalently bound under ATP consumption to several ubiquitin 
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molecules. This process is called ubiquitination. A further function is the 
marking of defective or denatured molecules or those, which were not correctly 
synthesized. These marked molecules will afterwards also be decomposed[45].  
Ubiquitin and its conjugates also play a significant role with other proteins in 
various biological functions such as in the regulation of the cell cycle[46, 47], in 
cell division[48], in DNA repair[49, 50], in the morphogenesis of neurons[45] and 
some other processes[51]. 
 
 
 
Figure 2.2.4.3: Ubiquitin consists of two α-helices and two β-sheet structures (from 
www.mdc-berlin.de/dittmar/ubiquitin.png). 
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2.3 Transfection methods 
Introducing DNA into eukaryotic cells is called transfection. This process 
involves the entry of extracellular molecules, such as plasmid DNA, siRNA or 
oligonucleotides, through the plasma membrane all the way to the nucleus.  
Such an introduction of desirable genetic sequences into mammalian cells is an 
essential tool for analyses of gene structure, function and regulation; it is also a 
medical technique that potentially allows the treatment of a wide variety of 
diseases of both genetic and acquired origin.  
The development of an efficient method for the introduction of therapeutic gene 
into cells is a major challenge in gene therapy. 
Gene delivery systems are generally divided into two categories, viral and non-
viral systems. 
 
 
2.3.1 Viral gene delivery systems 
Viral gene delivery systems are base on the ability to infect the cells[52]. It is the 
oldest method for gene transfer, which was first demonstrated on Salmonella in 
1952[53]. Later, for gene transfer into cells, different viral vectors based on 
retroviruses[54, 55], adenoviruses[56], adeno-assotiated viruses[57] and herpes 
simplex virus[58] and other viruses were used.  
In viral carriers, a part of the original gene segment is eliminated to have a space 
for the reporter gene to be placed. 
It is the most efficient method to transfer of DNA into cells, but it has serious 
drawbacks such as the risk of recombination, strong immunogenicity and 
carcinogenicity[56, 59, 60]. 
There are no methods available that would allow a safe and efficient viral-based 
gene delivery in the clinic[61]. Because of that, non-viral delivery systems have 
potential advantages for gene transfer even if they show a lower efficiency than 
virus-based systems. 
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2.3.2 Physical methods 
Electroporation[62, 63], microinjection[64] and gene gun techniques[65] belong to the 
physical methods. 
2.3.2.3 Electroporation 
Electroporation is a popular technique for introducing plasmid DNA into many 
cell types. Since 1982, electroporation has been used as a method for 
transfection of mammalian cells[66]. 
The application of electric pulses opens up pores in the cell membrane through 
which DNA can pass and directly enter into the cytoplasm. After initial 
permeabilization, the pores close and DNA is trapped within the cell[62, 63, 67]. 
This technique has been applied to introduce plasmid DNA into tissues such as 
muscles[68], melanoma[69], and liver[70]. 
A number of parameters, including the voltage and the length of the pulse, are 
important for optimal gene expression. However, there is a great variation in the 
efficiency with different cell types[68, 71].  
2.3.2.1 Microinjection 
The microinjection of naked plasmid DNA is the simplest method for DNA 
delivery. The drawback of the approach is that microinjection can reach only 
one cell at a time, i.e. it is not applicable for research with large numbers of cells 
and for DNA delivery in vivo[72]. 
It was shown that naked DNA cannot successfully enter cells unless it is assisted 
by a vector[73]. There are many reports about direct injection of naked DNA into 
the interstitial space of the corresponding tissue: skeletal muscle [74], liver [75], 
thyroid [76], heart muscle [77], brain [78], and urological organs [79].  
The uptake of plasmid DNA by injection is relatively inefficient (in muscle cells 
less than 1% of the injected dose)[74]. A tail vein injection of naked DNA into 
Viktoriya Sokolova, Dissertation 2006 
 26
mice did not result in gene expression in major organs[80], because of its rapid in 
vivo degradation by nucleases [81]. 
Therefore, the plasmid DNA needs to be protected from degradation before 
reaching the target cells.  
2.3.2.2 Gene gun 
Gene gun is the most recent physical transfection technology[82]. The full name 
of the gene gun is the “biolistic particle delivery system”. This technique is 
based on gold particles which are coated with DNA and shot into target tissues 
or cells[65]. There are a variety of different engineering strategies, but one way is 
to accelerate the particles using a pulse of helium. This approach allows DNA to 
penetrate directly through cell membranes into the cytoplasm or even the 
nucleus, and to bypass the endosomes, thus avoiding enzymatic degradation. 
The major limitation concerns the shallow penetration of particles into the 
tissue. The depth of the particle penetration in skeletal muscle of mouse did not 
exceed 0.5 mm[83].  
Skin, liver, and muscle were transfected by the gene gun technique. The 
efficiency of transfection varied among tissues, from 10 to 20 % for skin 
epidermal cells and from 1 to 5 % for muscle cells[65, 83, 84].  
However, in vivo gene gun application typically results in short-term and low-
level gene expression. Nevertheless, it might be suitable for genetic 
vaccination[85]. 
 
 
2.3.3 Chemical methods 
The chemical methods are generally based on nanoparticles which form a 
complex with DNA and serve as carriers. These methods can be divided into 
three big groups: Cationic compounds, recombinant proteins and inorganic 
nanoparticles. 
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2.3.3.1 Cationic compounds 
Felgner and co-workers[86] were the first to use the cationic lipid 
dioleoyltrimethylammonium chloride (DOTMA) in a 1:1 molar ratio with the 
neutral lipid dioleoylphosphatidylethanolamine (DOPE) to condense and 
transfect DNA. Since then, a variety of cationic lipids was developed for gene 
transfection. Lipids forms in water vesicular structure are termed liposomes, 
which can efficiently interact with DNA[87, 88]. 
The addition of cationic lipids to plasmid DNA decreases its negative charge, 
thus facilitates its interaction with cell membranes[89, 90]. Neutral lipids such as 
DOPE or cholesterol are generally added in cationic lipid-DNA complex to 
facilitate the release of plasmid DNA from the endosome in the cytoplasm[91].  
Some cationic lipid-DNA complexes were used in clinical trials[92, 93]. They 
could be successfully applied to deliver plasmid DNA to lung[94], brain[95], 
tumors[96, 97], and the skin[98]. 
One of the first polymers to be used in non-viral gene delivery was poly-L-
lysine (PLL)[99, 100]. PLL complexes with a size around 100 nm can be easily 
taken up by cells, although the transfection efficiency remained low[99]. The 
reporter gene expression could be improved by inclusion of targeting moieties 
such as chloroquine[101] or fusogenic peptides.  
Another polymer which is widely used for transfection is polyethylenimine 
(PEI). The major drawback of this polymer is its toxicity[102, 103]. Modified PEI 
particles were delivered to the liver[104] and to the lungs[105].  
The formulations of nanoparticles from biodegradable polymers aimed at gene 
delivery were also investigated. Poly(D,L-lactide-co-glycolide) (PLGA) and 
polylactic acid (PLA) were most extensively studied[106, 107].  
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2.3.3.2 Recombinant proteins 
Recombinant proteins are a special type of DNA vectors. These proteins have 
similar properties like viral vectors which are necessary for efficient gene 
delivery. 
Recombinant proteins may include polylysine segments, protamine, or histones 
to bind DNA to form stable complexes. Polylysine[108] and protamine[109, 110] 
have properties of DNA condensation which helps to protect DNA from 
nuclease degradation[110]. 
They may also contain antibodies, antibody segments for targeting cell delivery 
and some short peptide sequences acting as nuclear localisation signals. 
2.3.3.3 Inorganic nanopartcles 
Inorganic materials for DNA delivery such as calcium phosphate[111], carbon 
materials[112], silica[113], gold[114, 115], magnetite[116], strontium phosphate[117], 
magnesium phosphate and manganese phosphate[118], and double hydroxides[119, 
120] are widely used. 
Salem et al. reported about bi-metallic nanorods consisting of gold and nickel as 
a non-viral gene delivery system[121]. The gold and nickel segments in these 
nanorods can selectively bind plasmid DNA and target ligands. Small 
biomolecules can be loaded into carbon nanotubes[112]. Choy et al. reported 
about a biomolecular-inorganic hybrid, a class of anionic exchanging clays[119]. 
Because of its negative charge, DNA can be strongly incorporated into a layered 
double hydroxide. Gould et al. reported about iron oxide particles with 
diameters ranging from 300 nm to less than 10 nm, which serve as a carrier for 
DNA[122]. Bhakta et al. prepared magnesium and manganous phosphate 
nanoparticles with a particle size of 100-130 nm functionalized with DNA[118]. 
The standard calcium phosphate transfection method, originally discovered by 
Graham in 1977, is the cheapest one[111]. The preparation of the calcium 
phosphate carrier for transfection consists of a few steps: Mixing of calcium 
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chloride solution with DNA and addition of HEPES-buffered saline solution 
containing phosphate ions which results in the formation of fine precipitates of 
calcium phosphate with DNA. Calcium phosphate nanoparticles have a high 
biocompatibility and a good biodegradability compared to other types of 
nanoparticles used for cell transfection. 
In Table 2.3.3.1, different transfection methods are summarized and their 
advantages and disadvantages are shown. Viral carriers are most effective, but a 
rather dangerous method because of a risk of recombination. Electroporation is a 
safe, easy and rather efficient method, but it needs a large amount of DNA and 
has to be optimized for every cell type. Only one cell at a time can be 
transfected by microinjection which is not suitable for the whole organism. By 
gene gun technique a shallow penetration of DNA into the tissue is obtained. 
Cationic compounds and recombinant proteins can be used in clinical trials, but 
cationic compounds are rather toxic and recombinant proteins are expensive in 
preparation.  
Although inorganic nanoparticles show low transfection efficiencies, the 
advantages of inorganic nanoparticles over organic ones are that they are not 
subject to microbial attack, can be easily prepared, have low toxicity and exhibit 
good storage stability. Therefore, the development of inorganic nanoparticles 
with all required properties for the efficient and safe gene delivery is the main 
point of investigations. 
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Table 2.3.3.1: Comparison of different gene delivery systems 
 
Transfection  
method 
Advantages Disadvantages 
viral highly efficient immunogenicity, carcinogenicity 
electroporation easy to perform; 
efficient 
optimization for every cell line 
required; expensive; a lot of DNA is 
necessary 
microinjection exact direction of nucleic 
acid into a certain cell 
one cell at a time 
gene gun use for genetic vaccination shallow penetration of DNA into the 
tissue 
cationic compounds easily prepared high toxicity 
recombinant proteins high biocompatibility expensive 
inorganic 
nanoparticles 
easily prepared; size-
controllable; low toxicity 
low efficiency 
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2.4 RNA interference 
RNA interference (RNAi) is a process of sequence-specific post transcriptional 
gene silencing initiated by double-stranded siRNA (small interfering RNA). 
This phenomenon was discovered in the nematode Caenorhabditis elegans[123]. 
Later this process was extensively studied in other organisms including plants 
(Arabadopsis)[124], flies (Drosophila)[125], and humans[126, 127]. 
When long siRNA is delivered into the cell, it is processed by the RNase III-
type endonuclease Dicer into 21-25 bp functional small interfering 
RNA[128](Figure 2.4.1).  
 
 
 
Figure 2.4.1: Schematic representation of gene supression by RNA interference. I: Double 
stranded RNA, consisting of sense and anti-sense strands, is cleaved by Dicer to produce 
siRNAs. II: siRNA duplex. III: Incorporation of siRNA into a RISC complex and its 
unwinding by helicase activity. IV: Hybridization of an anti-sense agent to mRNA. V: 
Cleavage of target mRNA. 
 
The siRNAs subsequently assemble with protein components into an RNA-
induced silencing complex (RISC). The siRNA strands are then unwound to 
form activated RISCs. These activated RISCs then bind to complementary RNA 
molecules by base pairing interactions between the siRNA antisense strand and 
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the mRNA. The bound mRNA is cleaved and sequence specific degradation of 
mRNA results in gene silencing. 
In plants, worms and flies, the introduction of large siRNAs can efficiently 
induce gene silencing. This process has been also extended to mammalian cells 
with a few modifications. In mammalian system only short RNA duplexes of 
length approximately 21 bases can be used because longer siRNA evokes a 
nonspecific interferon response, which usually leads to nonspecific shutdown of 
protein synthesis and global RNA degradation[129]. Mammalian cells, in contrast 
to worms and flies, require a delivery system for RNA, such as a cationic lipid 
or calcium phosphate. 
RNAi technology has been successfully applied to identify genes with essential 
roles in biochemical signalling cascades, embryonic development, and other 
basic cellular process[130]. This technology is also widely applied for analyzing 
gene functions and for identifying and testing the new targets for diseases 
including cancer[131, 132]. 
 
Viktoriya Sokolova, Dissertation 2006 
 33
3 Results and Discussion 
3.1 Synthesis and characterization of DNA-functionalized calcium 
phosphate nanoparticles and their role as carriers for transfection 
Calcium phosphate is the inorganic component of many biological hard tissues, 
e.g. teeth and bone[133-135]. Therefore, it generally has a high biocompatibility 
which makes it suitable for the preparation of biomaterials[12]. In biochemistry, 
in situ precipitated dispersions of calcium phosphate are used for cell 
transfection[136, 137], i.e. for the non-viral introduction of DNA into living cells, 
first introduced by Graham et. al. in 1973[111]. 
Calcium phosphate nanoparticles are very well suited for cell transfection, 
because an in-situ precipitation of the inorganic salt in the presence of DNA 
gives nanoparticles which cells can immediately take up. This has been the 
subject of extensive investigations[111, 136-145]. The method is very easy and 
inexpensive, but the transfection efficiency is inferior to commercially available 
transfection agents which are based on liposomes[87, 88] and polymers[146].  
The standard calcium phosphate method strongly depends on the experimental 
parameters such as concentration, pH, precipitation time, type of DNA and also 
on the experimentalist[137, 142, 147, 148]. Consequently, it has to be optimized for 
every cell line and for every laboratory setting. The transfection solutions cannot 
be stored because the calcium phosphate nanocrystals grow with time into 
ineffective microcrystals. It was shown that the successful transfection of cells 
strongly depends on the particle size[113, 116, 136]. Organic and inorganic additives 
were therefore used to preserve the small size of calcium phosphate particles and 
to inhibit their subsequent growth. Chowdhury et al. prepared calcium 
phosphate nanoparticles with the addition of magnesium, causing an inhibition 
of the particle grow and a higher transfection efficiency[149]. Kakizawa et al. 
prepared nanoparticles consisting of calcium phosphate, DNA and block-
copolymers. A small size of the particles and good colloidal stability was 
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achieved by the steric effect of a poly(ethylene glycol) (PEG) layer surrounding 
the calcium phosphate core[145, 150]. 
Prabha et al. prepared PLGA nanoparticles by an emulsion evaporation 
technology. The smaller (70 nm) and larger nanoparticles (202 nm) were 
separately used for transfection. The small particles were 4-27 times more 
effective in the transfection than the large ones (depending on the cell line)[143]. 
Zhan et al. reported the preparation of superparamagnetic magnetite 
nanoparticles with a size of 10 nm, which were able to successfully penetrate the 
cell membrane[116]. 
Zhu et al. prepared oligonucleotide loaded microparticles with the size around 
20 µm from poly(lactide-co-glycolide)-polyethylene glycol as a local active 
substance[151]. Nsereko and Amiji prepared chitin particles with a similar size for 
the delivery of paclitaxel[152].  
The preparation of calcium phosphate nanoparticles especially for cell 
transfection was extensively carried out and investigated. Roy et al. reported the 
preparation of DNA incorporated calcium phosphate nanoparticles and the 
influence of DNA on the crystallinity of calcium phosphate[136]. The particles 
were crystalline without and amorphous with DNA. Jordan et al. varied in a 
systematic way the calcium and phosphate concentrations, the precipitation 
temperature and the precipitation time and studied the transfection efficiency. 
One minute of precipitation time gave the highest transfection efficiency. A 
longer time results in a decrease of the transfection efficiency. At a very high 
concentration of DNA the precipitation was completely inhibited, which 
suggests a clear interaction between DNA and calcium phosphate[139]. The time 
between precipitation solutions and their addition to the cells played a critical 
role. Depending on the precipitation method an increase or decrease of the 
transfection efficiency within 1 to 30 min was observed[148].  
Yang and Yang studied the transfection efficiency of calcium phosphate 
precipitates as a function of cell medium, pH and time by transmission electron 
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microscopy. They observed a growth of the initially developed small crystallites. 
The crystallite sizes were approximately 50-100 nm. The pH was varied 
between 6.48 and 10.01 during the precipitation[140]. Seelos reported about time-
dependent transfection experiments. If a freshly precipitated calcium phosphate 
developed into larger crystals, then the transfection was less effective. There is 
an inhibitory effect of proteins in the growth medium which has a strong 
influence on the crystal growth[148].  
According to the current state of knowledge, calcium phosphate nanoparticles 
are incorporated into the cells by endocytosis (penetration of the cell membrane 
and uptake into an intracellular vesicle). DNA has to overcome several physical 
and chemical barriers before it can enter the nucleus (Figure 3.1.1), e.g. 
intracellular degradation in lysosomes in the cytoplasm[39, 153].  
 
 
Figure 3.1.1: Schematic representation of the transfection mechanism[154]. 
 
Some studies were carried out to elucidate the pathway of DNA. Strain et al. 
found less than 7 % of the applied DNA inside the cells and less than 4 % in the 
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nucleus. Only 0.5 % of DNA was still undegraded and active[138]. Orrantia and 
Chang studied the way of 32P-marked DNA into the cell and concluded that the 
morphology of the colloids and the protection from degrading enzymes played 
an important role for the transfection efficiency[147, 155]. Loyter et al. carried out 
investigations with 3H-marked DNA to show the importance of the nanoparticle 
morphology (mainly the particle size)[153].  
Taking into account all previously discussed, we can say that for a successful 
transfection it is important to have well-defined nanoparticles, which should be 
as small as possible. Nanoparticles have to incorporate the DNA, in order to 
prevent its intracellular degradation by enzymes. 
Welzel et al. have shown how nanoparticles of calcium phosphate can be 
prepared with defined particles size[156] and how custom-made DNA-
functionalized calcium phosphate nanoparticles can be used for cell 
transfection[154]. However, the colloid-chemical characterization of these 
nanoparticles was very preliminary, and there were some larger aggregates 
within the dispersions. 
We demonstrate how stable dispersions can be prepared by variation of the 
inorganic part of the system, i.e. by substitution of cations within the calcium 
phosphate, and how DNA can be incorporated into the particles. This is a major 
goal for a potential biochemical application because DNA on the outside of 
particles is easily degraded within a cell and therefore cannot reach the nucleus. 
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3.1.1 Plasmid DNA, pcDNA3-EGFP, applied for transfection 
Enhanced green fluorescent protein (EGFP) is a commonly used reporter 
system[157]. When this EGFP gene is successfully incorporated into the cell’s 
genome, it causes the synthesis of enhanced green fluorescent protein, which 
can be detected by fluorescence microscopy. The emission of fluorescent light 
occurs, when EGFP exited at a wavelength of around 488 nm[157]. In this work 
plasmid DNA, pcDNA3-EGFP, was used. It was used for the stabilization of 
colloids and at the same time for the determination of the transfection efficiency.  
It is difficult to determine the size of plasmid DNA by electron microscopy, 
therefore the size of DNA was estimated as follows.  
The information shown below was used for the calculation: 
1. The size of pcDNA3 is 5441 bp; 
2. The molar mass of the whole vector is 1 871 704 g mol-1, which came 
from the multiplication of the average molar mass of one nucleotide (344 
g mol-1) by the size of the plasmid DNA (5441 bp) 
3. The density of DNA is approximately 1.42 g cm-3 [158] 
The volume of one mol is 1318101.4 cm3 mol-1 which comes from the equation: 
 Vm = M ρ-1 (M is the molar mass; ρ is the density of DNA)  
If molar volume is divided by Avogadro constant (Na), the volume of one DNA 
molecule is 2.19·10-18 cm3. 
From  
 
V = 4/3 πr3 
 
the radius of a sphere of plasmid DNA is 8.04 nm, consequently its diameter is 
about 16 nm. 
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3.1.2. Optimization of calcium and phosphate concentration and the 
amount of DNA 
Calcium phosphate nanoparticles were prepared by rapid mixing of aqueous 
solutions of calcium and phosphate, followed by addition of DNA to the formed 
dispersion. (Figure 3.1.2.1).  
 
Figure 3.1.2.1: Schematic setup of the apparatus used for preparation of DNA-functionalized 
calcium phosphate nanoparticles. Calcium nitrate and diammonium hydrogen phosphate 
solutions are mixed in a vessel to form a precipitate. A part of the dispersion is taken with a 
syringe and mixed with DNA solution in an Eppendorf tube. 
 
Our goal was to prepare stable colloids with small nanoparticles up to 100 nm in 
size. First of all we had to find the optimal concentration parameters to prevent 
the formation of larger particles and thereby precipitation. Two different 
concentrations of  calcium (6.25 mM and 18 mM) and phosphate (3.74 mM and 
10.8 mM) with the stoichiometric ration, corresponding to hydroxyapatite, 
Ca5(PO4)3OH (Ca:PO4=n:n=1.67) were used.  A solution with the concentration 
of calcium (6.25 mM) and phosphate (3.74 mM) gave the best results after 
addition of DNA for colloidal stabilization.  
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The amount of DNA on the surface of such nanoparticles influenced their charge 
which can be estimated by the zeta potential. The negatively charged DNA 
reversed the initially positive surface charge to negative values. In Figure 3.1.2.2 
it can be seen that there is no change above about 0.2 mL DNA solution, i.e. we 
assume that the surface was fully covered with DNA at or above this 
concentration.  
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Figure 3.1.2.2: Effect of the amount of DNA solution ([DNA]=1 mg mL-1) on the surface 
charge (expressed by the zeta potential) of the colloids (1 mL calcium phosphate dispersion 
with 6.25 mM Ca2+ and 3.74 mM PO43- in all cases). There is no further adsorption of DNA 
above about 0.2 mL. 
 
The influence of the amount of DNA on the particle size was also studied. The 
results from dynamic light scattering measurements are presented in Table 
3.1.2.1. The optimal amount of DNA (0.2 mL) was found at which the colloid is 
monodisperse consisting of nanoparticles with diameter 36 nm. When the 
amount of DNA was lower than 0.2 mL, larger particles were observed. When 
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the amount of DNA was too high (0.3 mL and more), the polydispersity index 
(PDI) was very high, i.e. different fractions of particles were present. 
 
Table 3.1.2.1: Colloid-chemical data of functionalized calcium phosphate nanoparticles with 
different amounts of DNA ([DNA]=1 mg mL-1). The volume of calcium phosphate dispersion 
before mixing with DNA was always 1 mL. The percentages in the particle distributions give 
the volume distribution of the particles from dynamic light scattering. PDI denotes 
polydispersity index. 
 
Sample DNA 
/ mL 
PDI Size of 
particles / nm 
% Zeta potential 
/ mV 
A 0.1 0.3 74 88 -29 (5) 
B 0.2 0.25 36 98 -33 (4) 
C 0.4 0.6 26 92 -32 (4) 
D 0.6 0.5 22 99 -33 (7) 
E 0.8 0.6 11 100 -31 (6) 
F 1.0 0.5 37 100 -38 (3) 
G 1.2 0.6 15 100 -37 (9) 
H 1.4 0.6 13 99 -36 (5) 
 
Analytical ultracentrifugation was used to see if all DNA was adsorbed on the 
surface or if there was free DNA in solution. Figure 3.1.2.3 shows typical 
distributions of the sedimentation coefficient for pure DNA and for the colloidal 
dispersion. From integration of the peak for DNA (s=1 to 5·10-13 s) it can be 
derived that about 10 % of DNA was free in the colloidal dispersion and that 
consequently about 90 % were bound to the surface of the particles. 
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Figure 3.1.2.3: Sedimentation coefficient distribution of pure aqueous DNA solution (solid 
line; 0.5 mg mL-1), and of calcium phosphate/DNA colloids (dashed line; 6.25 mM Ca2+ and 
3.74 mM PO43- with 1 mL of DNA of 1 mg mL-1). The peaks at 1.5 and 2.5 correspond to free 
DNA and the peak at 12 corresponds to the DNA-coated calcium phosphate nanoparticles. 
There is almost no free DNA in the colloidal dispersion (Table 3.1.2.1 sample F). 
 
 
3.1.3. Optimization and characterization of calcium phosphate/DNA 
nanoparticles with additions of magnesium and aluminum 
To prevent the particle growth, magnesium and aluminum were tested as 
additives. Magnesium is a well known inhibitor of calcium phosphate crystal 
growth[149, 159]. The incorporation of the trivalent aluminum may introduce a 
higher positive charge when it substitutes for the divalent calcium. The addition 
of magnesium will be first discussed. 
The initial concentration of magnesium (3 mM, 6 mM, 9 mM, 12 mM, 15 
mM) was varied at a low concentration of calcium and phosphate (6.25 and 3.74 
mM). Results from analytical ultracentrifugation are shown in Figure 3.1.3.1. It 
Viktoriya Sokolova, Dissertation 2006 
 42
can be clearly seen that the smallest sedimentation coefficient was found at 
magnesium concentration of 6 mM (S=10), i.e. the particles had the smallest 
size. If the concentration of magnesium was lower or higher than 6 mM, at this 
concentration the particle size is increased (Figure 3.1.3.1) 
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Figure 3.1.3.1: Sedimentation coefficient distribution of pure aqueous DNA solution (0.5 mg 
mL-1) and of calcium phosphate/DNA colloids with addition of magnesium with different 
concentration (3 mM; 6mM; 9 mM; 12 mM). Arrows show the peaks at the corresponding 
concentration of magnesium. The peaks at 1.5 and 2.5 correspond to free DNA. There is no 
free DNA in the colloidal dispersion. Nanoparticles were prepared at the low concentration of 
calcium and phosphate (1mL; 6.25 mM and 3.74 mM) with 1.0 mL of DNA (1 mg mL-1). 
 
Particle size and DNA adsorption were studied by dynamic light scattering and 
analytical ultracentrifugation. The nanoparticles in the presence of magnesium 
were smaller in comparison to nanoparticles without magnesium. The optimal 
concentration of magnesium was 6 mM which led to two fractions with a 
particle size around 11 nm and 76 nm (Table 3.1.3.1; sample D). Analytical 
Viktoriya Sokolova, Dissertation 2006 
 43
ultracentrifugation again confirmed the almost complete adsorption of DNA on 
the surface of the particles, i.e. almost no free DNA was detected (comparable to 
Figure 3.1.2.3). If calcium was absent, i.e. if pure magnesium phosphate was 
precipitated, a particle size of about 32 nm was obtained (Table 3.1.3.1; sample 
E).  
The initial concentration of aluminum was also varied (1 mM, 2 mM, 4 mM). 
Figure 3.1.3.2 shows the results from analytical ultracentrifugation for calcium 
phosphate  nanoparticles  with addition of aluminum. As aluminum  can be toxic 
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Figure 3.1.3.2: Sedimentation coefficient distribution of calcium phosphate/DNA colloids 
with addition of aluminum with different concentration (1 mM; 2 mM; 4 mM). Arrows show 
the peaks at the corresponding concentration of aluminum. Nanoparticles were prepared at the 
low concentration of calcium and phosphate (1 mL; 6.25 mM and 3.74 mM) with 1.0 mL of 
DNA (1 mg mL-1) (Table 3.1.3.1; sample G). 
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for cells, e.g. in transfection studies, a small concentration of aluminum was 
chosen. Calcium phosphate/DNA nanoparticles with the addition of aluminum 
(2 mM) showed a good inhibitory effect on the particle size (S=8.7 compared to 
that of calcium phosphate/DNA without aluminum S=11.3). By analytical 
ultracentrifugation was found that the optimal concentration of aluminum was 2 
mM at the low concentration of calcium and phosphate (6.25 and 3.74 mM) (see 
Figure 3.1.3.2). 
Aluminum and magnesium both inhibited the growth of the nanoparticles. Small 
particles with about 21 nm in diameter were obtained according to dynamic light 
scattering. This corresponded well to TEM results (Figure 3.1.3.3). 
 
 
Figure 3.1.3.3: Transmission electron micrograph of calcium phosphate nanoparticles with 
addition of aluminum, functionalized by 1.0 mL DNA. The particles had a typical size of 15 
to 30 nm (Table 3.1.3.1; sample G).  
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In contrast, we found larger particles when we prepared aluminum phosphate 
colloids, i.e. without calcium (Table 3.1.3.1; sample H). In this case, the particle 
size was up to 306 nm with aggregates. However, DNA adsorbed with high 
efficiency if aluminum was present as shown by the strongly negative zeta 
potential. This might be ascribed to an initially more positive surface charge if 
Al3+ substituted for Ca2+ which in turn increased the adsorption of the negatively 
charged DNA. 
To compare the morphology and size of pure calcium phosphate nanoparticles to 
those with addition of magnesium and aluminum different methods of analysis 
were used. It is possible to compare the size of three types of 
0 2 4 6 8 10 12 14 16
0.0
0.2
0.4
0.6
0.8
1.0
CaP
CaMgP
g(
s)
s / S . 10-13 s
DNA CaAlP
 
Figure 3.1.3.4: Sedimentation coefficient distribution of pure aqueous DNA solution (0.5 mg 
mL-1). Arrows denote the peaks corresponding to DNA, calcium phosphate/DNA colloids 
without and with additions of aluminum and magnesium. Nanoparticles were prepared at the 
low concentration of calcium (6.25 mM), phosphate (3.74 mM), magnesium (6 mM) and 
aluminum (2 mM) with 1.0 mL of DNA (1 mg mL-1). 
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nanoparticles, calcium phosphate/DNA (CaP), calcium phosphate/DNA with 
aluminum (CaAlP) and calcium phosphate/DNA with magnesium (CaMgP). 
The results from analytical ultracentrifugation measurements are represented in 
Figure 3.1.3.4. The nanoparticles with addition of magnesium or aluminum were 
smaller in comparison to nanoparticles without those. 
SEM pictures show the morphology of the calcium phosphate nanoparticles with 
the addition of magnesium; magnesium phosphate and aluminum phosphate 
nanoparticles (Figure 3.1.2.5). All types of particles have a spherical 
morphology.  
The schematic representation of the particle size is shown in Figure 3.1.3.6. 
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Figure 3.1.3.5: Scanning electron micrographs of calcium phosphate nanoparticles with 
additions of magnesium (A); magnesium phosphate (B) and aluminum phosphate 
nanoparticles (C). Nanoparticles were prepared at the low concentration of calcium (6.25 
mM), phosphate (3.74 mM), magnesium (6 mM) and aluminum (4 mM) with 0.2 mL of DNA 
(1 mg mL-1) (Table 3.1.3.1; samples D, E, H). 
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Calcium phosphate/DNA nanoparticles showed a particle size around 36 nm, 
with addition of aluminum the size decreased to 21 nm and with magnesium two 
different fractions with the size 11 nm and 76 nm were observed (Figure 
3.1.3.6). Magnesium phosphate/DNA nanoparticles were also small (32 nm). 
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20
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Figure 3.1.3.6: Schematic representation of the particle size for pure calcium phosphate and 
for calcium phosphate precipitated in the presence of aluminum or magnesium by dynamic 
light scattering. All colloids were stabilized with 0.2 mL DNA (1 mg mL-1); sample numbers 
(Table 3.1.3.1). given in parentheses. 
 
At the high concentration of calcium and phosphate (18 mM and 10.8 mM) we 
also obtained small nanoparticles with a hydrodynamic diameter of 35 nm 
(Table 3.1.3.1; sample I). 
 
 
Viktoriya Sokolova, Dissertation 2006 
 48
 
Table 3.1.3.1: Colloid-chemical data of functionalized calcium phosphate nanoparticles. The volume of calcium phosphate dispersion before 
mixing with DNA (1 mg mL-1) was always 1 mL (s*=sedimentation coefficient from analytical ultracentrifugation). The percentages in the particle 
distributions give the volume distribution of the particles from light scattering.  
 
Sample Zeta 
potential 
 / mV 
Size of small 
particles 
 / nm 
% Size of large 
particles 
 / nm 
% s / S · 10-13 s 
 [Ca2+] 
/ mM 
[HPO42-] / 
mM 
DNA 
 / mL 
[Mg2+] / 
mM 
[Al3+] / 
mM 
      
A 18 10.8 - - - 3(3) 346 30 1961 70 - 
B 6.25 3.74 - - - 0.5(3) - - 1320 100 - 
C 6.25 3.74 0.2 - - -33(4) 36 99 - - 16 
D 6.25 3.74 0.2 6.0 - -25(4) 11 63 76 33 - 
E - 3.74 0.2 6.0 - -25(4) 32 99 - - - 
F 6.25 3.74 0.2 - 2.0 -28(4) 21 99 - - - 
G 6.25 3.74 1.0 - 2.0 -35 (4) 40 90 225 2 8.7 
H - 3.74 0.2 - 4.0 -66(5) 82 47 306 22 - 
I 18 10.8 0.2 - - -32(5) 35 92 272 5 19 
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3.1.4 Transfection experiments with calcium phosphate/DNA nanoparticles 
The DNA-loaded calcium phosphate nanoparticles were prepared by a 
straightforward precipitation method (Figure 3.1.2.1). The transfection was 
carried out with the DNA-loaded calcium phosphate nanoparticles with the 
fluorophor protein coding for plasmid DNA, pcDNA3-EGFP. As control, the 
standard calcium phosphate method and a commercial dendrimer-based 
transfection agent (Polyfect®) were used. The amounts of DNA in the different 
transfection experiments were comparable (see Experimental chapter 4.5). 
For the preliminary experiments, T-HUVEC (transformed human umbilical vein 
endothelial cells) were used. T-HUVEC were obtained after spontaneous 
transformation of primary HUVEC[160] which are good in vitro models for 
understanding the mechanism of angiogenesis which plays a critical role in 
many physiological processes[161]. Furthermore, they are models for endothelial 
cell-derived tumors. 
The results are summarized in Table 3.1.4.1. The transfection efficiency using 
Polyfect® (9.9 %) was the highest as expected, and was used as reference. Using 
the standard calcium phosphate method we obtained about 2.5 % transfected 
cells while the calcium phosphate/DNA nanoparticles gave up to 3.1 % (at the 
low concentration of calcium and phosphate of 6.25 mM and 3.74 mM) and 3.5 
% (at the high concentration of 18 mM and 10.8 mM). The transfection 
efficiency of calcium phosphate/DNA nanoparticles with additions of 
magnesium (6 mM) and aluminum (2 mM) was 2.1 % and 2.6 % respectively. 
For magnesium phosphate/DNA (at the concentration of magnesium of 6 mM) 
and aluminum phosphate/DNA nanoparticles (at the concentration of aluminum 
of 4 mM) the transfection efficiency was below 1 % and could not be quantified. 
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Table 3.1.4.1: Results of all transfection experiments with T-HUVEC in serum-free RPMI 
1640 medium (average of several experiments; 0.2 mL DNA with 1 mg mL-1 calcium 
phosphate solution; 3.3 µg DNA per transfection). Nanoparticles were prepared at the low 
concentration of calcium and phosphate (6.25 mM and 3.74 mM). For the calcium 
phosphate/DNA nanoparticles dispersion at a high concentration of calcium and phosphate 
(18 mM and 10.8 mM) the transfection efficiency is given in parentheses (Table 3.1.3.1; 
samples C, D, E, F, H). 
 
Method Transfection efficiency / % 
Polyfect® 9.9 ± 3.8 
Standard calcium phosphate precipitation method  2.5 ± 2.1 
Calcium phosphate/DNA nanoparticles  
3.1 ± 1.3  
(3.5 ± 0.8) 
Calcium phosphate/DNA nanoparticles with the addition 
of magnesium (6 mM) 
2.1 ± 0.4 
Calcium phosphate/DNA nanoparticles with the addition 
of aluminum (2 mM) 
2.6 ± 0.5 
Magnesium phosphate/DNA nanoparticles (6 mM) < 1 % 
Aluminum phosphate/DNA nanoparticles (4 mM) < 1 % 
 
It is important to note that at a high concentration of calcium and phosphate (18 
mM, 10.8 mM) the transfection efficiency was higher compared to the low 
concentration (6.25 mM and 3.74 mM) and easier to reproduce. Therefore, for 
further experiments the high concentration was used. 
Futher transfection experiments were carried out with T-HUVEC and two other 
cell lines (HeLa and LTK) in different media. These cell lines were a 
representative choice out of cell lines typically used in cell biology: T-HUVEC 
(human, endothelial cells), HeLa (human, epithelial cells), and LTK (mouse, 
fibroblasts). HeLa and LTK cells were easier to transfect with Polyfect® or other 
non-viral vectors than T-HUVEC (Table 3.1.4.2). However, for DNA-loaded 
calcium phosphate nanoparticles, the transfection efficiency was somewhat 
higher for HeLa cells (4-10 %, depending on the medium) and almost the same 
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for LTK and T-HUVEC (2-4 %). The transfection efficiency also depended on 
the cultivation medium (Table 3.1.4.2). The efficiency increased when serum-
free (i.e. protein-free) medium was used as solvent for the DNA-coated 
nanoparticles. This is probably due to an interaction between protein and 
nanoparticles. The reason for this behaviour is not known, but there may be an 
interaction between the DNA-coated surface and the chemically affine proteins 
that leads to bridging and agglomeration. 
 
Table 3.1.4.2: Results of all transfection experiments with HeLa, LTK and T-HUVEC 
(average of several experiments; 0.2 mL DNA with 1 mg mL-1 calcium phosphate solution; 
3.3 µg DNA per transfection). Nanoparticles were prepared at the high concentration of 
calcium and phosphate (18 mM and 10.8 mM). 
 
Transfection efficiency / % Cell line Method 
Quantum® 
medium 
RPMI 1640 
with FCS 
Serum-free 
RPMI 1640 
Polyfect® 19.4 ± 0.6 18.3 ± 3.8 31.6 ± 5.4 
Standard calcium phosphate 
precipitation method  
4.5 11.7 22 
HeLa 
Calcium phosphate/DNA 
nanoparticles 
4.0 ± 0.3 4.2 ± 1.6 10.0 ± 2.4 
Polyfect® 17.4 ± 0.2 9.9 ± 2.3 21.9 ± 5.4 
Standard calcium phosphate  
precipitation method  
6.2 8.3 9.5 
LTK 
Calcium phosphate/DNA 
nanoparticles 
2.4 ± 0.6 2.2 ± 0.2 3.9 ± 0.6 
Polyfect® 9.9 ± 4.0 10.9 ± 3.0 9.9 ± 3.8 
Standard calcium phosphate  
precipitation method  
2.8 ± 2.5 5.2 ± 0.2 2.5 ± 2.1 
T-HUVEC 
Calcium phosphate/DNA 
nanoparticles 
2.9 ± 0.6 2.7 ± 1.2 3.5 ± 0.8 
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In all cases, the transfection efficiency was smaller with the calcium phosphate 
nanoparticles than with the commercial agent (Polyfect®). Consequently, we 
tried to increase the efficiency of the nanoparticles by variation of the accessible 
parameters such as the amount of DNA and pH. First we studied the effect of the 
amount of DNA in the dispersion on the transfection efficiency. Only 
insignificant differences were observed with T-HUVEC, even with a fivefold 
amount of DNA (Figure 3.1.4.1).  
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Figure 3.1.4.1: Effect of the amount of DNA ([DNA]=1 mg mL-1) in the colloids on the 
transfection efficiency of T-HUVEC cultured in different media. The corresponding amounts 
of DNA per transfection were 1.8 µg (0.1 mL), 3.3 µg (0.2 mL), 4.6 µg (0.3 mL), 5.7 µg (0.4 
mL), and 6.7 µg (0.5 mL). The variation in the transfection efficiency was not significant. 
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The scatter in the results is probably statistically insignifican. We conclude that 
a simple increase of the amount of DNA (going from 1.8 µg to 6.7 µg) does not 
increase the transfection efficiency. However, it is also not clear whether all 
DNA was really adsorbed on the particles or whether it was merely dissolved in 
the solution.  
It is well known that DNA itself, i.e. without a nanoparticle as carrier, is not 
active in transfection[38, 78]. A variation of the pH during precipitation of calcium 
phosphate also did not noticeably influence the transfection efficiency in 
contrast to the common experience with the classical method where the 
deviation from pH 7.1 showed dramatically decrease in the transfection 
efficiency[147, 162]. Using the calcium phosphate/DNA nanoparticles precipitated 
at pH 7 we could obtain 3 % transfected cells in Quantum® medium and up to 
5.7 % transfected cells in serum-free RPMI 1640 medium. The transfection 
efficiency of calcium phosphate/DNA nanoparticles in transfection mixtures 
containing FCS was below 1 % and could not be quantified.  
Presumably, the reason for the low transfection efficiency is the attack of 
nucleases within the cytoplasm which prevents the transfer of calcium 
phosphate/DNA nanoparticles into the nucleus[39]. Therefore an encapsulation of 
DNA could increase the efficiency, similar to the action of liposomes or 
polymers[87, 88, 146]. 
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3.1.5 Conclusion 
It was demonstrated how nanodisperse calcium phosphate/DNA nanoparticles 
with a size below 100 nm can be prepared by a comparatively easy and well 
reproducible process, especially if calcium is partially substituted by magnesium 
or aluminum. These ions obviously have an inhibitory effect on the particle 
growth of calcium phosphate. 
The cell experiments (T-HUVEC) showed that the transfection efficiency of the 
calcium phosphate/DNA nanoparticles yielded up to 3.1 % or 3.5 % (depending 
on the concentration of calcium and phosphate) and is comparable with the 
results from the standard calcium phosphate method (2.5 %). The transfection 
efficiency of calcium phosphate/DNA nanoparticles with additions of 
magnesium and aluminum was not as high as we expected (2.1 % and 2.6 %), 
although in these colloids the nanoparticles had the smallest size. In fact, the 
reason of the low transfection efficiency may be the degradation of DNA by 
nucleases in the cells. 
These functionalized nanoparticles formed a stable colloid and did not lose their 
properties after several weeks of storage in contrast to the standard calcium 
phosphate method.  
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3.2 Multi-shell calcium phosphate/DNA nanoparticles as carriers 
for the transfection 
In the previous chapter it was shown that custom-made nanoparticles of calcium 
phosphate can be efficiently coated and colloidally stabilised by DNA and then 
used for cell transfection[163]. The advantage of this preparation in comparison to 
the common in-situ precipitation method is a much better control over size and 
composition of these particles. However, it turned out that the transfection 
efficiency of such nanoparticle dispersions could not be increased further even 
by variation of the amount of DNA or the nature of the nanoparticles 
(precipitation conditions).  
Before the DNA successfully enters the nucleus, it has to overcome several 
physical and chemical barriers, e.g. intracellular degradation in lysosomes[39, 153]. 
We assumed that the particles were taken up by the cells but then internally 
digested by nucleases. Therefore the DNA needs to be protected from such an 
attack by incorporation into the particle. In the following we demonstrate how 
this can be accomplished by preparing multi-shell particles. 
 
 
3.2.1 Characterization of multi-shell calcium phosphate/DNA nanoparticles 
Multi-shell nanoparticles with a calcium phosphate core and DNA/calcium 
phosphate shells can be prepared by subsequent precipitation/functionalization 
(Figure 3.2.1.1). The goal was to protect the DNA from degradation within the 
cell by incorporating it into the particle. We used two different concentrations of 
the calcium (6.25 mM and 18 mM) and phosphate (3.74 mM and 10.8 mM) 
solutions to prepare multi-shell calcium phosphate nanoparticles (Table 3.2.1.1).  
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Figure 3.2.1.1: Schematic representation of the three types of calcium phosphate/DNA 
nanoparticles. 
 
The particle size was smaller if the outer layer consisted of DNA (single- and 
triple-shell; see Figures 3.2.1.2 and 3.2.1.3 and Table 3.2.1.1). If calcium 
phosphate was on the outside, aggregation occurred, probably due to the absence 
of electrostatic and steric stabilization (see below). The zeta potential of single- 
and triple-shell nanoparticles was very similar (-32 and -30 mV), and their 
density should also be comparable, therefore we tentatively assume that there 
was an increase in size when going from single-shell to triple-shell particles. 
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Figure 3.2.1.2: Sedimentation coefficient distributions of calcium phosphate/DNA colloids 
with single-shell, double-shell and triple-shell nanoparticles. Arrows show the peaks 
corresponding to DNA (0.5 mg mL-1), single-shell, double-shell and triple-shell calcium 
phosphate/DNA nanoparticles (Table 3.2.1.1; samples D, E, F). Nanoparticles were prepared 
at the low concentration of calcium (6.25 mM) and phosphate (3.74 mM) with 0.2 mL of 
DNA (1 mg mL-1). 
 
For samples which contained DNA, we frequently observed a large peak in 
dynamic light scattering. This was also present if only DNA was dissolved in 
water. Because the dispersions did not show sedimentation and because no large 
aggregates were found in ultracentrifugation, we tentatively ascribed this 
phenomenon to DNA-water aggregates that do not contain calcium phosphate. 
The peaks in light scattering could not be removed by filtration. Visually, the 
samples did not show large aggregates (in contrast to the samples B, E in Table 
3.2.1.1, which were not colloidally stabilised and showed sedimentation). 
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Figure 3.2.1.3: Sedimentation coefficient distributions of calcium phosphate/DNA colloids 
with single-shell and triple-shell nanoparticles. Arrows show the peaks corresponding to DNA 
(0.5 mg mL-1), single-shell and triple-shell calcium phosphate/DNA nanoparticles (Table 
3.2.1.1; samples A, B, C). Nanoparticles were prepared at the high concentration of calcium 
(18 mM) and phosphate (10.8 mM) with 0.2 mL of DNA (1 mg mL-1).  
 
The alternating layer structure of the multi-shell particles was demonstrated by 
their zeta potential which is a qualitative measure of the particle charge. 
Calcium phosphate particles without DNA carry almost no charge ("CaP"). A 
coating with DNA renders the particles strongly negative ("single-shell"). The 
addition of another external layer of calcium phosphate ("double-shell") 
compensates most of this negative charge, and the outer layer of DNA makes the 
particles negatively charged again (Fig. 3.2.1.4). This effect depends on the 
amount of calcium phosphate which is used to prepare the second layer.  
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Figure 3.2.1.4: Dependence of the zeta potential from the type of nanoparticles. Solid line: 
Nanoparticles at high concentration of calcium and phosphate (18 mM and 10.8 mM) with 0.2 
mL of DNA (1 mg mL-1); dashed line: Nanoparticles at low concentration of calcium and 
phosphate (6.25 mM and 3.74 mM) with 0.2 mL of DNA (1 mg mL-1) (Table 3.2.1.1; samples 
A/D, B/E, C/F). 
 
If there is not enough calcium phosphate present (e.g. 6.25 mM/3.74 mM), it is 
not sufficient to fully cover the surface and some DNA groups are left exposed, 
thereby giving the particle a still considerably negative charge. The double-shell 
particles with calcium phosphate on the outside were not stable towards 
aggregation, probably due to the absence of steric and electrostatic stabilization 
(Table 3.2.1.1, samples B and E). Unfortunately, it was not possible to visualize 
the internal structure of the multi-shell particles by transmission electron 
microscopy due to strong radiation damage at high magnification. 
As shown in Figure 3.2.1.5, multi-shell nanoparticles had the same spherical 
shape, but a different size. The average particle diameter (z-average) from 
dynamic light scattering was almost the same at high and low concentrations of 
Viktoriya Sokolova, Dissertation 2006 
 60
calcium and phosphate: around 35 nm (PDI=0.2) for single-shell particles, 
around 75 nm (PDI=0.4) for double-shell particles and around 45 nm (PDI=0.6) 
for triple-shell particles (Table 3.2.1.1; samples A-F). The particle diameter 
increased with the number of shells, but the simultaneously increasing 
polydispersity index (PDI) showed that we probably had a mixture of smaller 
and larger particles with an increasing number of shells. This supports the 
assumption that the particles had a core-shell-structure. 
200 nm
200 nm 200 nm
 
Figure 3.2.1.5: Scanning electron micrograph of single-shell (A), double-shell (B) and triple-
shell (C) calcium phosphate/DNA nanoparticles (Table 3.2.1.1; samples D, E, F). 
Nanoparticles were prepared at the low concentration of calcium and phosphate (6.25 mM 
and 3.74 mM) with 0.2 mL of DNA (1 mg mL-1).  
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Table 3.2.1.1: Colloid-chemical data of functionalized calcium phosphate nanoparticles. The volume of calcium phosphate dispersion before 
mixing with DNA was always 1 mL (s*=sedimentation coefficient from analytical ultracentrifugation). The percentages in the particle distributions 
give the volume distribution of the particles from light scattering. The large aggregates in some samples containing DNA on the outside ("single" 
and "triple") are probably due to DNA-water aggregates and not to large calcium phosphate particles (see text). 
 
Sample Zeta potential 
 / mV 
Size of small 
particles 
 / nm 
% Size of large 
particles 
 / nm 
% s / S · 10-13 s 
 No. of 
shells 
[Ca2+] 
/ mM 
[HPO42-] / 
mM 
DNA 
 / mL 
      
A single 18 10.8 0.2 -32(5) 35 92 272 5  
B double a) 18 
b) 18 
a) 10.8 
b) 10.8 
a) 0.2 
- 
-7(11) 76 11 736 83 - 
C triple a) 18 
b) 18 
a) 10.8 
b) 10.8 
a) 0.2 
c) 0.2 
-30(4) 45 48 788 50 24 
D single 6.25 3.74 0.2 -33(4) 36 99 - - 16 
E double a) 6.25 
b) 6.25 
a) 3.74 
b) 3.74 
a) 0.2 
- 
-26(6) 75 70 295 20 23 
F triple a) 6.25 
b) 6.25 
a) 3.74 
b) 3.74 
a) 0.2 
c) 0.2 
-33(5) 46 54 1046 45 17 
 
Viktoriya Sokolova, Dissertation 2006 
 62
3.2.2. Transfection efficiency of multi-shell nanoparticles 
There are a number of carriers of organic and inorganic nature which 
incorporate DNA, thereby protecting it from degrading enzymes[118, 146, 164]. 
Therefore, three types of nanoparticles were developed to investigate the effect 
of DNA protection and the role of small particles for a successful transfection 
(Figure 3.2.1.1)  
For transfection experiments with multi-shell nanoparticles, T-HUVEC was 
selected, because this cell line showed the lowest transfection efficiency and 
therefore any improvement would be better seen in this case. For DNA 
protection an external layer of calcium phosphate on DNA-coated calcium 
phosphate nanoparticles was prepared by crystallization (denoted "double-shell" 
in Figure 3.2.1.1). This results in the formation of core-shell particles with a 
calcium phosphate core, a layer of DNA causing the expression of EGFP, and an 
outer calcium phosphate shell. Because such a system is not stable for long 
towards agglomeration (no protective DNA layer), we prepared triple-shell 
particles with another layer of DNA for colloidal stabilization. The main idea 
was to prevent the crystal growth by the adsorption of the outer layer of DNA on 
the nanoparticle surface which leads to electrostatic stabilization of the colloid 
(denoted "triple-shell" in Figure 3.2.1.1). These three kinds of particles were 
used for transfection experiments with T-HUVEC. Depending on the 
transfection method T-HUVEC show large differences in transfection 
efficiencies which helps to detect even small improvements of the method. 
Multi-shell nanoparticles at different concentrations of calcium (6.25 mM and 
18 mM) and phosphate (3.74 mM and 10.8 mM) were tested on the cells. The 
results from transfection experiments are discussed here. 
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Table 3.2.2.1: Results of transfection experiments with T-HUVEC from numerical analysis 
of the laser fluorescence micrographs. The efficiencies are given as average ± standard 
deviation (N=3). Nanoparticles were prepared at the low concentration of calcium and 
phosphate (6.25 mM and 3.74 mM).  
 
Transfection efficiency / % Method 
Quantum® 
medium 
RPMI 1640 
with FCS 
Serum-free 
RPMI 1640 
Polyfect® 9.9 ± 4.0 10.9 ± 3.0 9.9 ± 3.8 
Standard calcium phosphate  
precipitation method  
2.8 ± 2.5 5.2 ± 0.2 2.5 ± 2.1 
Single-shell calcium phosphate/DNA-  
nanoparticles  
3.2 ± 1.8 3.2 ± 2.1 3.1 ± 1.3 
Double-shell calcium phosphate/DNA- 
nanoparticles 
2.5 ± 0.8 2.4 ± 1.0 3.4 ± 0.7 
Triple-shell calcium phosphate/DNA-  
nanoparticles 
4.6 ± 0.6 3.3 ± 1.1 4.3 ± 0.2 
 
 
In Table 3.2.2.1 the results of transfection experiments with T-HUVEC at a low 
concentration of calcium and phosphate are shown. We obtained transfection 
efficiency between 2 to 4 % for all type of calcium phosphate/DNA 
nanoparticles. The reason for this low efficiency can be a lack of the particles in 
the solution or not enough calcium and phosphate for the shell formation. 
It is important to note that at a high concentration of calcium and phosphate the 
results from transfection experiments were significantly better. We observed a 
continuous increase of the transfection efficiency when going from single-shell 
to triple-shell nanoparticles from 3.5 % up to 10 % in serum-free RPMI1640. 
With the standard calcium phosphate method we achieved about 5 % of 
transfected cells and with the commercial transfection agent Polyfect® about 10 
%. The results are summarized in Table 3.2.2.2. Figure 3.2.2.1 shows the cell 
morphology and EGFP fluorescence after transfection (T-HUVEC). 
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Figure 3.2.2.1: Transmission light microscopy (upper row) and EGFP fluorescence 
microscopy (lower row; magnification 200 x in all cases) of T-HUVEC that were transfected 
with the commercial transfection agent Polyfect® (A), with standard calcium phosphate 
precipitation method (B), and with calcium phosphate/pcDNA3-EGFP nanoparticles in 
serum-free RPMI medium (C: single-shell nanoparticles, D: double-shell, E: triple-shell; 
according to Figure 3.2.1.1). Transfected cells appear green as a whole due to EGFP 
fluorescence. The increase in transfection efficiency from C to E is obvious. 
 
The transfection efficiency did not depend strongly on the type of medium 
within the limits of reproducibility. Single-shell particles were comparable to the 
classical precipitation method, demonstrating that the principle is the same in 
both kinds. The addition of another layer of calcium phosphate considerably 
increased the transfection efficiency, supporting our concept. The efficiency of 
calcium phosphate-mediated transfection with triple-shell particles was 
comparable to that of Polyfect®. For all three media, the results are graphically 
represented in Figures 3.2.2.2-3.2.2.4. 
Viktoriya Sokolova, Dissertation 2006 
 65
Table 3.2.2.2: Results of transfection experiments with T-HUVEC from numerical analysis of the laser fluorescence micrographs. The efficiencies 
are given as average ± standard deviation (N=3). For the nanoparticle dispersions, the transfection efficiencies are also given in parentheses after 2 
weeks of storage at 4°C (N=1). There was no significant decrease in the transfection efficiency after storage. Nanoparticles were prepared at the 
high concentration of calcium and phosphate (18 mM and 10.8 mM) 
 
Transfection efficiency / % Method 
Quantum® medium RPMI 1640 with FCS Serum-free RPMI 1640 
Polyfect® 9.9 ± 4.0 10.9 ± 3.0 9.9 ± 3.8 
Standard calcium phosphate  
precipitation method  
2.8 ± 2.5 5.2 ± 0.2 2.5 ± 2.1 
Single-shell calcium phosphate/DNA 
nanoparticles  
2.9 ± 0.6 
(2.4) 
2.7 ± 1.2 
(3.9) 
3.5 ± 0.8 
(3.9) 
Double-shell calcium phosphate/DNA 
nanoparticles 
5.6 ± 2.8 
(6.7) 
4.9 ± 1.7 
(4.9) 
6.2 ± 2.4 
(7.0) 
Triple-shell calcium phosphate/DNA 
nanoparticles 
9.4 ± 3.3 
(10.1) 
6.1 ± 2.6 
(5.5) 
9.8 ± 6.5 
(5.0) 
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Figure 3.2.2.2: Comparison of the transfection efficiency of T-HUVEC in Quantum® 
medium by different methods. The error bars represent the standard deviation (N=3). There 
were significant differences between single-shell and triple-shell (P<0.01) and triple-shell and 
the standard calcium phosphate method (P<0.05) 
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Figure 3.2.2.3: Comparison of the transfection efficiency of T-HUVEC in RPMI 1640 
medium with FCS by different methods. The error bars represent the standard deviation 
(N=3). 
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Figure 3.2.2.4: Comparison of the transfection efficiency of T-HUVEC in RPMI 1640 
medium without FCS by different methods. The error bars represent the standard deviation 
(N=3).  
 
As it was shown in chapter 3.2.1, the particles have a core-shell structure and at 
least in this case, the charge does not play a critical role for the transfection 
efficiency, otherwise we would not observe a continuous increase in transfection 
efficiency with the number of shells. 
We also tried to extend the procedure and to add more shells of calcium 
phosphate and DNA, in order to further increase the transfection efficiency. 
Unfortunately, the efficiency does not increase after the addition of more layers, 
probably because of an increasing polydispersity and simultaneous 
crystallisation-reprecipitation processes (no detailed light scattering experiments 
were carried out with these systems). 
The particle dispersions could be stored at 4°C for two weeks and all dispersions 
(single-, double- and triple-shell) kept their transfection efficiency (T-HUVEC; 
Table 3.2.2.2). The storage was not continued thereafter, but we assume that the 
storage time could in principle be even longer. 
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3.2.3 Conclusion  
By a comparatively easy and well reproducible process we prepared multi-shell 
calcium phosphate/DNA-nanoparticles with a calcium phosphate core and 
DNA/calcium phosphate shells. Such shells help to protect DNA from the 
degradation by enzymes (nucleases) inside the cytoplasm of cultured endothelial 
cells, reaching the efficiency of Polyfect®. In principle, different layers can 
sequentially deliver different agents[165]. Calcium phosphates should be 
advantageous due to their high biocompatibility and good biodegradability 
compared to other types of nanoparticles used for cell transfection such as iron 
oxide (magnetite)[166], silica[113] or gold[115]. In contrast to the classical calcium 
phosphate method, the particle/DNA dispersions can be stored for weeks 
without loss of their transfection efficiency. It was shown by the high 
transfection efficiency that the DNA remained intact in the multi-shell particles. 
It may be assumed that the DNA inside the particle is the most active and that it 
should be possible to substitute the DNA on the outside (which is mainly used 
for colloidal stabilization) by other agents like double-hydrophilic block-
copolymers[167]. 
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3.3 Calcium phosphate colloids containing protamine: Colloidal 
and biochemical properties 
Many advancements were made over the past several years in the field of non-
viral gene therapy to improve gene delivery and expression to the cells both in 
vitro and in vivo. The uptake of isolated genes by tissue culture cells was used 
widely to test for gene function, for treating genetic diseases[168]. 
Calcium phosphate nanoparticles are good carriers due to such characteristics as 
non-toxicity, high biocompatibility, good biodegradability, and simplicity of 
large-scale production and use. Our purpose was to make them more efficient in 
cell transfections and targetable to become cell-specific.  
The cell membrane generally represents an impenetrable barrier for the transport 
of biomolecules like DNA or polypeptides[169], therefore, a drug delivery system 
is required.  
In recent years, the knowledge of the unique property of viruses to penetrate into 
cells and to deliver their genetic material was applied and studied in non-viral 
gene delivery systems. Viral proteins, so-called TAT proteins (TAT=trans-
activating transcriptional activator), play a very important role in the trafficking 
of nanoparticles into the cell and especially in the overcoming of DNA the 
nuclear membrane barrier. As reported by Pante et al., the maximum size of the 
macromolecules for the passage through the nuclear pore complex is about 39 
nm[170]. Larger molecules must possess a nuclear localization sequence (NLS) to 
pass through the nuclear pores. The use of TAT proteins and derived peptides 
for the intracellular delivery of drug carriers can dramatically increase the 
transfection efficiency. 
Some researchers have reported the increase of the transfection efficiency of 
magnetic nanoparticles in the presence of TAT peptides[171-173]. Torchilin et al. 
demonstrated the successful delivery of large liposomes (with a size of 200 nm) 
with attached TAT-peptide molecules[174]. 
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In our studying protamine was chosen to expert a specific role in our DNA 
delivery system. Protamine is a basic protein with a molecular weight of 
approximately 4000 to 10000. Protamine has four possible nuclear localization 
sequences consisting of basic amino acids and proline or serine residues[168, 175, 
176] (for details see chapter 2.2.4.1).  
 
 
3.3.1 Mechanism of the transfer of calcium phosphate/DNA/protamine 
nanoparticles  
Figure 3.3.1.1 represents the schematic illustration of the DNA delivery 
pathway. As a first step, calcium phosphate nanoparticles should be formed. 
Positively charged protamine[177] can neutralize a negative charge of DNA and 
provide an approach of nanoparticles to negatively charged cell membrane via 
electrostatic interaction (Figure 3.3.1.1, I). Then nanoparticles move into the 
cytoplasm by endocytosis.  
After calcium phosphate/DNA/protamine nanoparticles escape from endosomes 
and are released into the cytoplasm, they meet importins there. Protamine, which 
is adsorbed on the surface of nanoparticles, binds with importins by NLS 
(Figure 3.3.1.1, IV). These nanoparticles with importins approach the external 
nuclear membrane and attach on the cytoplasmatic filaments of the pore 
complex. It is not yet clearly understood whether whole nanoparticles enter the 
nucleus or only the plasmid DNA[178]. 
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Figure 3.3.1.1: Schematic illustration of transfer mechanism of calcium phosphate/DNA 
nanoparticles in addition of protamine into a cell. I: Formation of calcium 
phosphate/DNA/protamine nanoparticles and their uptake. II: Endocytosis. III: Escape from 
endosomes and intracellular release. IV: Binding to importin. V: Nuclear targeting. VI: 
Nuclear entry and gene expression. 
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3.3.2 Characterization of colloids with protamine 
The calcium phosphate/DNA nanoparticles were functionalized at protamine 
concentrations from 0.5 to 20 mg mL-1. The colloidal properties were studied in 
dependence of the concentration of protamine. 
It was observed that by increasing the concentration of protamine the size of 
particles became smaller. This tendency is clearly seen from 1.0 to 10 mg mL-1. 
The solution with a protamine concentration of 10 mg mL-1 gave the smallest 
particles and the highest transfection efficiency. Further addition of protamine in 
the solution led to an increasing particle size (Table 3.3.2.1). The average 
particle diameter (z-average) from dynamic light scattering was 288 nm 
(PDI=0.3) for single-shell particles, 177 nm (PDI=0.2) for double-shell particles, 
and 80 nm (PDI=0.7) for triple-shell particles. The particle diameter decreased 
with the number of shells, but the simultaneously increasing polydispersity 
index (PDI) showed that we probably had a mixture of smaller and larger 
particles with an increasing number of shells. 
Protamine is a positively charged molecule which is interacting with the 
negative charge of the phosphate groups in DNA molecule. The interaction 
behaviour of calcium phosphate/DNA nanoparticles with protamine is 
elucidated by zeta potential measurements. By an addition of protamine (1 mg 
mL-1) the nanoparticles assumed a positive charge (Figure 3.3.2.1). The single- 
and triple-shell nanoparticles were less negatively charged compared to the 
nanoparticles without protamine (-30 mV). At a protamine concentration of 5 
mg mL-1, the charge of DNA was fully neutralized and the zeta potential of 
nanoparticles became slightly positive (around +5 mV) (Table 3.3.2.1). 
For characterization, we also used transmission and scanning electron 
microscopy.  
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Table 3.3.2.1: Colloid-chemical data of functionalized calcium phosphate/DNA/protamine 
nanoparticles. The volume of the calcium phosphate dispersion before mixing with DNA was 
always 1 mL. The percentages in the particle distributions give the intensity distribution of the 
particles from light scattering. 
 
Sample Z-Average 
(nm) 
PDI Zeta 
potential  
/mV 
A Single-shell calcium phosphate/DNA/protamine 
nanoparticles (1 mg mL-1) 
379 0.3 -20 
B Double-shell calcium phosphate/DNA/protamine 
nanoparticles (1 mg mL-1) 
578 0.2 -7 
C Triple-shell calcium phosphate/DNA/protamine 
nanoparticles (1 mg mL-1) 
493 0.4 -11 
D Single-shell calcium phosphate/DNA/protamine 
nanoparticles (5 mg mL-1) 
221 0.4 0 
E Double-shell calcium phosphate/DNA/protamine 
nanoparticles (5 mg mL-1) 
355 0.4 7 
F Triple-shell calcium phosphate/DNA/protamine 
nanoparticles (5 mg mL-1) 
543 0.5 2 
G Single-shell calcium phosphate/DNA/protamine 
nanoparticles (10 mg mL-1) 
288 0.3 1 
H Double-shell calcium phosphate/DNA/protamine 
nanoparticles (10 mg mL-1) 
177 0.2 5 
I Triple-shell calcium phosphate/DNA/protamine 
nanoparticles (10 mg mL-1) 
80 0.7 1 
J Single-shell alcium phosphate/DNA/protamine 
nanoparticles (20 mg mL-1) 
236 0.3 4 
K Double-shell calcium phosphate/DNA/protamine 
nanoparticles (20 mg mL-1) 
213 0.4 5 
L Triple-shell calcium phosphate/DNA/protamine 
nanoparticles (20 mg mL-1) 
391 0.4 6 
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Figure 3.3.2.1: Dependence of the zeta potential from the concentration of protamine in 
single-, double- and triple-shell calcium phosphate/DNA/protamine nanoparticles.  
 
Figure 3.3.2.2 shows typical electron micrographs of triple-shell nanoparticles 
functionalized with protamine. The particles had a spherical shape with a size of 
about 50 to 80 nm. 
 
 
 
Figure 3.3.2.2: Scanning electron micrograph of triple-shell calcium 
phosphate/DNA/protamine nanoparticles (10 mg mL-1) (Table 3.3.2.1; sample I). 
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3.3.3 Transfection efficiency of calcium phosphate/DNA/protamine 
nanoparticles 
Transfection experiments were carried out with T-HUVEC in three different 
media. The influence of the content of protamine on the transfection efficiency 
was studied. The experiments with 0.5 to 5 mg mL-1 and 20 mg mL-1 of 
protamine showed no significant variation in transfection efficiency (Table 
3.3.3.1). Up to 5 % of transfected cells were observed. However, the transfection 
efficiency was somewhat higher for double-shell nanoparticles with 5 mg mL-1 
of protamine (5.1 to 8.6 % of transfected cells depending on the cell culture 
medium).  
As expected, single-shell nanoparticles with different concentrations of 
protamine in all three media showed a low transfection efficiency (up to 5 %). 
The reason is an attack of nucleases within the cytoplasm, which destroy DNA 
and prevent its transfer and incorporation into the nucleus. Protamine in single-
shell nanoparticles cannot protect DNA from the degradation like the calcium 
phosphate shells in double- and triple-shell nanoparticles. The optimal 
concentration of protamine was 10 mg mL-1 which showed the highest 
transfection efficiency. The transfection efficiency was 7-8 % for double-shell 
nanoparticles and 9-14 % for triple-shell nanoparticles. 
For all three media, the results from Table 3.3.3.1 are graphically represented in 
Figures 3.3.3.1-3.3.3.3. 
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Table 3.3.3.1: All results of transfection experiments carried out with functionalized calcium phosphate/DNA/protamine nanoparticles. 
Transfektion efficiency / % Methode 
Quantum® 
medium 
RPMI 1640 
with FCS 
Serum-free 
 RPMI 1640 
Single-shell calcium phosphate/DNA nanoparticles 2.3 1.4 1.2 
Double-shell calcium phosphate/DNA nanoparticles 3.2 1.9 3.8 
Triple-shell calcium phosphate/DNA nanoparticles 4 3.7 5.1 
Single-shell calcium phosphate/DNA/protamine nanoparticles (0.5 mg mL-1) 4.9 3.3 2.9 
Double-shell calcium phosphate/DNA/protamine nanoparticles (0.5 mg mL-1) 4.7 2.4 3.7 
Triple-shell calcium phosphate/DNA/protamine nanoparticles (0.5 mg mL-1) 3.7 2.6 4.0 
Single-shell calcium phosphate/DNA/protamine nanoparticles (1 mg mL-1) 1.8 1.2 2.2 
Double-shell calcium phosphate/DNA/protamine nanoparticles (1 mg mL-1) 2.7 2.5 5.5 
Triple-shell calcium phosphate/DNA/protamine nanoparticles (1 mg mL-1) 2.1 1.3 1.4 
Single-shell calcium phosphate/DNA/protamine nanoparticles (5 mg mL-1) 2.1 1.8 1.9 
Double-shell calcium phosphate/DNA/protamine nanoparticles (5 mg mL-1) 6.7 8.6 5.1 
Triple-shell calcium phosphate/DNA/protamine nanoparticles (5 mg mL-1) 2.9 5.4 4.5 
Single-shell calcium phosphate/DNA/protamine nanoparticles (10 mg mL-1) 5.0 3.8 3.0 
Double-shell calcium phosphate/DNA/protamine nanoparticles (10 mg mL-1) 7.2 8.0 6.8 
Triple-shell calcium phosphate/DNA/protamine nanoparticles (10 mg mL-1) 14.4 10.6 8.9 
Single-shell calcium phosphate/DNA/protamine nanoparticles (20 mg mL-1) 5.0 2.0 3.0 
Double-shell calcium phosphate/DNA/protamine nanoparticles (20 mg mL-1) 5.0 3.5 4.0 
Triple-shell calcium phosphate/DNA/protamine nanoparticles (20 mg·mL-1) 9.0 10.0 4.0 
Viktoriya Sokolova, Dissertation 2006 
 77
 
Figure 3.3.3.1: Effect of the concentration of protamine in single-, double- and triple-shell 
calcium phosphate nanoparticles on the transfection efficiency of T-HUVEC in Quantum® 
medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3.3.2: Effect of the concentration of protamine in single-, double- and triple-shell 
calcium phosphate nanoparticles on the transfection efficiency of T-HUVEC in RPMI 1640 
medium without FCS. 
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Figure 3.3.3.3: Effect of the concentration of protamine in single-, double- and triple-shell 
calcium phosphate nanoparticles on the transfection efficiency of T-HUVEC in RPMI 1640 
medium with FCS. 
 
Such results are corresponding to the mechanism proposed by Masuda et al.[179]. 
The protamine molecule possesses different functions: As a condenser of DNA 
by its arginine residues and as a nuclear localization signal. At a low 
concentration of protamine (below 10 mg mL-1), all basic amino acids of 
protamine may be consumed in the condensation of DNA. Therefore, the 
recognition of the NLS by the nuclear transport-associating proteins (importins) 
is limited. At the optimal concentration of protamine (10 mg mL-1), the 
protamine with NLS is displayed on the surface of the particles, allowing the 
particles to be recognized by nuclear transport-associating proteins. 
The transfection efficiency was lower at a protamine concentration of 20 mg 
mL-1. The reason could be that free protamine may interact with nuclear 
transport-associating proteins[179] and, therefore, inhibit the nuclear transfer of 
DNA. 
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Figure 3.3.3.4: Transmission light microscopy (upper row) and EGFP fluorescence 
microscopy (lower row; magnification 200 x in all cases) of T-HUVEC that were transfected 
with calcium phosphate/pcDNA3-EGFP nanoparticles with addition of  protamine (10 mg 
mL-1) in RPMI medium with FCS (A: single-shell, B: double-shell, C: triple-shell 
nanoparticles). Transfected cells appear green as a whole due to EGFP fluorescence. 
 
Figure 3.3.3.4 shows the transfection efficiency observed by microscopy. All 
cells are presented in transmission light microscopy and only transfected cells 
appear as green cells in fluorescence microscopy. As a control we used calcium 
phosphate/DNA nanoparticles without protamine to show the effect of 
protamine on the transfection efficiency.  
At the optimal concentration of protamine, the transfection efficiency was better 
than in control experiments. There was no significance, but the tendency of the 
increasing transfection efficiency can be clearly seen (Figure 3.3.3.5-3.3.3.7).  
Protamine supplied sufficient positive charge to completely neutralize the 
phosphodiester backbone of DNA. As a consequence of this neutralization, the 
DNA was condensed into a compact particle[168]. 
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The reason of a more effective transfection with calcium 
phosphate/DNA/protamine nanoparticles can also be the compensation of the 
negative charge of DNA by positively charged protamine molecules, thereby 
improving the uptake by cells. Protamine/DNA nanoparticles (i.e. without 
calcium phosphate) showed no transfection efficiency in control experiments. 
 
Table 3.3.3.2: Results of transfection experiments with T-HUVEC by numerical analysis of 
laser fluorescence micrographs. The efficiencies are given as average ± standard deviation 
(N=3).  
 
Transfektion efficiency, % Method 
Quantum® 
medium 
RPMI 1640 
with FCS 
Serum-free 
RPMI 1640 
Polyfect® 9.9 ± 4.0 10.9 ± 3.0 9.9 ± 3.8 
Standard calcium phosphate precipitation 
method  
2.8 ± 2.5 5.2 ± 0.2 2.5 ± 2.1 
Single-shell calcium phosphate/DNA 
nanoparticles 
2.9 ± 0.6 2.7 ± 1.2 3.5 ± 0.8 
Double-shell calcium phosphate/DNA 
nanoparticles  
5.6 ± 2.8 4.9 ± 1.7 6.2 ± 2.4 
Triple-shell calcium phosphate/DNA 
nanoparticles 
9.4 ± 3.3 6.1 ± 2.6 9.8 ± 6.5 
Single-shell calcium phosphate/DNA/ 
protamine nanoparticles (10 mg mL-1) 
4.3 ± 1.5 4.6 ± 1.3 3.5 ± 0.6 
Double-shell calcium phosphate/DNA/ 
protamine nanoparticles (10 mg mL-1) 
9.7 ± 4.6 8.3 ± 2.6 8.3 ± 2.1 
Triple-shell calcium phosphate/DNA/ 
protamine nanoparticles (10 mg mL-1) 
9.5 ± 0.8 12.7 ± 8.4  11.5 ± 4.4 
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Figure 3.3.3.5: Comparison of the transfection efficiency of T-HUVEC in RPMI 1640 
medium without FCS by different methods. The error bars represent the standard deviation 
(N=3). 
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Figure 3.3.3.6: Comparison of the transfection efficiency of T-HUVEC in RPMI 1640 
medium with FCS by different methods. The error bars represent the standard deviation 
(N=3).  
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Figure 3.3.3.7: Comparison of the transfection efficiency of T-HUVEC in Quantum® 
medium by different methods. The error bars represent the standard deviation (N=3).  
 
The highest transfection efficiencies were found for nanoparticles in RPMI 1640 
with FCS medium (up to 13 %) (Figure 3.3.3.6). The efficiency for triple-shell 
nanoparticles with protamine was almost two times better compared to those 
without protamine (12.7 % vs. 6.1 %). In all these cases we can talk only about 
the tendency of improvement in transfection efficiency, but not about true 
significance of the results, because the standard deviation is large.  
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3.3.4 Conclusion 
Calcium phosphate/DNA/Protamine nanoparticles were prepared and 
characterized. Protamine was used to improve the efficiency of DNA delivery 
into cells. In vitro transfection studies showed that calcium 
phosphate/DNA/protamine nanoparticles had a higher transfection efficiency 
compared to calcium phosphate/DNA nanoparticles without protamine and as 
high as a commercially available transfection agent (Polyfect®). 
Protamine plays an important role in neutralization of negatively charged DNA 
molecules and their condensation, which cause an easier interaction of the 
nanoparticles with negatively charged membrane and their successful 
penetration into cells. Protamine also provides the direct nuclear import of 
DNA. However, statistically significant effect of protamine was not found. 
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3.4 Tracking the pathway of calcium phosphate/DNA  
Over the past few years, the intracellular trafficking of plasmid DNA was 
extensively studied, because it is one of the major challenges for efficient gene 
delivery[139, 140]. For successful cell transfection (the non-viral introduction of 
DNA into eukaryotic cells), a variety of extracellular and intracellular barriers 
must be overcome. There are some major physical barriers: The plasma 
membrane, the cytoskeletal network and the nuclear membrane[38, 180, 181]. In 
previous chapters the development of DNA-coated calcium phosphate 
nanoparticles for cell transfection was shown. Transfection rates comparable to 
commercial transfection agents (Polyfect®) were achieved with multi-shell 
nanoparticles. The dispersions could be stored for weeks without loss of 
transfection efficiency. 
General questions remain as to the way of the nanoparticles into the cell and 
their route within the cell. To address this question, we used the red-
fluorescencing marker tetramethylrhodamine isothiocyanate (TRITC) bound to 
bovine serum albumin (BSA) as a marker. Nanoparticles functionalized with 
pcDNA3-EGFP for transfection and TRITC-BSA for labeling were prepared. As 
control, we prepared calcium phosphate nanoparticles functionalized with 
TRITC-BSA only, and also nanoparticles (aggregates) of pcDNA3-EGFP and 
TRITC-BSA, i.e. without a calcium phosphate core. 
By fluorescence microscopy and laser confocal microscopy we followed the 
way of the three types of nanoparticles in contact with T-HUVEC cells. 
Thereby, the efficiency of transfection (green fluorescence) as well as the 
distribution of the nanoparticles (red fluorescence) could be compared. 
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3.4.1 Particle characterization  
The results of dynamic light scattering are shown in Table 3.4.1.1. In the 
colloidal dispersion of CaP/BSA, two fractions with a particle size around 11 
nm and 268 nm were found, as well as for CaP/DNA/BSA with sizes of 12 nm 
and 276 nm and for DNA/BSA with sizes of 9 nm and 329 nm. Scanning and 
transmission electron microscopies confirmed the presence of two fractions of 
nanoparticles (Figure 3.4.1.1-3.4.1.2). All particles carry a strongly negative 
charge, as evidenced by the zeta potential, due to the negatively charged 
phosphate groups of adsorbed DNA. The particle size distributions of all 
samples were very similar. 
 
Table 3.4.1.1: Colloid-chemical data of functionalized calcium phosphate nanoparticles. 
PDI=Polydispersity index from dynamic light scattering. The size ratio refers to intensity 
distributions.  
 
Sample PDI 
 
Size of small 
particles / nm 
% Size of large 
particles / nm 
% Zeta potential / 
mV 
CaP/DNA 0.2 35 92 272 5 -32 
CaP/BSA 0.3 11 56 268 35 -40 
CaP/DNA/BSA 0.7 12 46 276 51 -30 
DNA/BSA 0.4 9 22 329 40 -38 
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Figure 3.4.1.1 Scanning electron micrographs of CaP/BSA (A) and CaP/DNA/BSA 
nanoparticles (B). The particle size confirms the results from dynamic light scattering. 
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Figure 3.4.1.2: Transmission electron micrographs of CaP/DNA/BSA (A) and CaP/BSA 
nanoparticles (B). The particle size confirms the results from dynamic light scattering. 
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3.4.2 Experiments with cells 
3.4.2.1 Calcium phosphate/BSA nanoparticles (CaP/BSA) 
Fluorescence microscopy and laser confocal microscopy were used to follow the 
trafficking of fluorescence-labeled nanoparticles into T-HUVEC in vitro (Figure 
3.4.2.1). Within the first hour of transfection with CaP/BSA nanoparticles, the 
nanoparticles accumulated on the plasma membrane. After two hours, the 
nanoparticles were observed in the cytoplasm. During the next hours, the 
nanoparticles were transported towards the nucleus. After 24 hours all 
nanoparticles were found near the nuclear membrane.  
 
 
Figure 3.4.2.1: The endocytosis of CaP/BSA nanoparticles in T-HUVEC was monitored 
using transmission light microscopy (top) and fluorescence microscopy (bottom). In the upper 
row, cells and nanoparticles (black dots) can be seen. Arrows on fluorescent microscopy 
images in the lower row show the CaP/BSA nanoparticles as fluorescing dots in the cells. 
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3.4.2.2 Calcium phosphate/DNA/BSA nanoparticles (CaP/DNA/BSA) 
The intracellular fate of CaP/DNA/BSA nanoparticles was similar to that of 
CaP/BSA nanoparticles in the absence of DNA. In this case we could also see 
whether DNA was successfully incorporated into the nucleus. i.e. whether or not 
a transfection occurred. In Figure 3.4.2.2, the way of nanoparticles into the cells 
is shown. Nanoparticles were accumulated on the plasma membrane and went 
into the cells after 2 hours of transfection.  
 
Figure 3.4.2.2: Transmission light microscopy (top row), fluorescence microscopy (center 
row) and overlay of both pictures (bottom row) of T-HUVEC transfection experiments. In 
light microscopy, all cells and their nuclei are visible. In the central row, the CaP/DNA/BSA 
nanoparticles appear as bright red dots. Arrows indicate binding of nanoparticles to the cell 
surface after 2 h (A), penetration into the cytoplasm after 8 h (B), and accumulation on the 
nuclear membrane after 48 h (C). After 48 hours, the transfected cells appear green with 
incorporated red-fluorescing nanoparticles (D). 
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Already after 8 hours many nanoparticles were attached to the nuclear 
membrane. The successful incorporation of plasmid DNA into the nucleus was 
detected using pcDNA3-EGFP which coded for EGFP. Only the transfected 
cells show the green fluorescence of EGFP (Figure 3.4.2.2, D). Laser confocal 
microscopy showed that the nanoparticles were accumulated inside the cells in 
the case of successfully transfected cells (Figure 3.4.2.3). 
A B
C
 
 
Figure 3.4.2.3: Laser confocal microscopy of T-HUVEC transfection experiments. A green 
fluorescing transfected cell after 48 hours is shown (A). The CaP/DNA/BSA nanoparticles 
appear as red fluorescing dots (B). The particles are localized inside the cell (C; overlay of A 
and B). 
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3.4.2.3 DNA/BSA nanoparticles (DNA/BSA) 
In contrast, the cells treated with DNA/BSA (i.e. without calcium phosphate) 
remained dark regardless of the incubation time because the cells could not take 
up TRITC or BSA even at high concentration (Figure 3.4.2.4). The fluorescing 
aggregates of DNA/BSA neither entered the cells nor adhered to the cell 
membrane and were completely removed by washing.  
 
Figure 3.4.2.4: Transmission light microscopy and fluorescence microscopy of T-HUVEC 
after 2 hours of transfection with DNA/BSA nanoparticles. In light microscopy all cells can 
be seen (A); by fluorescence microscopy no bright dots were found, i.e. all red-fluorescing 
particles were removed by washing and no transfection occurred (B). 
 
 
Our results correspond well to the literature: Choy et al. showed that the marker 
FITC alone can not pass into the cells[119]. It is obvious that calcium phosphate 
plays an important role in mediating the cellular uptake of TRITC-BSA and 
DNA. Plasmid DNA routing is a very complicated process consisting of many 
physico-chemical barriers which have to be overcome for efficient gene 
expression. The current literature gives a number of studies on the mechanism of 
intracellular trafficking of nucleic acids after crossing the cell membrane. 
Lukacs et al. examined DNA mobility through the cytoplasm and found that 
larger DNA fragments were unable to diffuse through the cytoplasm. No 
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diffusion through the cytoplasm was observed for DNA fragments > 2000 base 
pairs in length [182]. It was assumed that DNA within endosomes after 
endocytosis is traveling towards the nucleus by a yet unknown process[153, 183]. 
Unprotected DNA is degraded within minutes by nucleases presented in 
cytoplasm[38, 39, 184, 185]. 
There are three major intracellular processes that can influence on the successful 
trafficking of plasmid DNA into the nucleus: Endocytosis, endosome escape and 
nuclear targeting.  
To summarize the results from the experiments and the literature the illustration 
of DNA trafficking can be set up following (Figure 3.4.2.5). 
 
 
 
Figure 3.4.2.5: Representation of DNA trafficking into the cell. I-II: A successful trafficking 
of DNA directly into the nucleus and its expression. Two ways of DNA degradation are 
shown: A: Degradation in endosomes. Endosome, containing DNA, fuses with lysosome. The 
degradation of DNA occurs under influence of variety of hydrolytic enzymes inside the 
lysosome. B: Degradation in the cytoplasm by nucleases. 
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Nanoparticles are usually too large to pass through ion channels into the plasma 
membrane, therefore they enter the cell by endocytosis[153, 183]. Endocytosis 
involves the deformation of the plasma membrane and the formation of 
endosomal vesicles, containing the nanoparticles.  
Plasmid degradation can occur during endocytosis inside endosomes. 
Endosomal degradation is a multi-step process. Carrier vesicles transfer the 
nanoparticles with DNA from the early endosomes compartment (with pH 6.3-
6.8) to the late endosomes compartment (with pH 5-5.5). If DNA does not 
escape from endosomes before the fusion with lysosomes (with pH > 5) [186], 
then endosomal degradation takes place (Figure 3.4.2.5, A). When the 
nanoparticles with DNA are successfully released into the cytoplasm from 
endosomes before their fusion with lysosomes, they can suffer an attack by 
nucleases, which can degrade the DNA (Figure 3.4.2.5, B). 
For efficient transfection DNA has to survive the attack of cytoplasmic 
nucleases and to enter the nucleus. During the trafficking of plasmid DNA in the 
cytoplasm, DNA must escape from the endosome prior to fusion with lysosomes 
and be liberated into the cytoplasm before nuclear targeting[178, 181, 187]. 
Nuclear targeting was studied by many researchers [64, 188-190]. However, it is still 
not clear when DNA is detached from the nanoparticles. One of the possibilities 
is that calcium phosphate nanoparticles are slowly dissolved by acid in the 
endosomal vesicle and DNA is released into the cytoplasm. Another possibility 
is that nanoparticles with DNA go to the nucleus where the import of DNA can 
occur. In this case, DNA can be protected until its incorporation into the nucleus 
which causes an increase in transfection efficiency[163].  
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3.4.3 Conclusions  
We have demonstrated the comparatively easy preparation of calcium phosphate 
nanoparticles functionalized with DNA and fluorescence-marked with TRITC-
BSA. SEM observations and dynamic light scattering analysis showed that all 
nanoparticles had spherical morphology with sizes between 10 nm and 300 nm.  
Fluorescence microscopy and laser confocal microscopy studies were used to 
follow the pathway of these nanoparticles into the cells. The nanoparticles were 
adsorbed on cellular membrane after 2 h and could be found in the cytoplasm 
after 8 h where they accumulated then near the nuclear membrane. The 
transfection efficiency correlates with the distribution of the nanoparticles in the 
cells. DNA/BSA aggregates alone are not able to penetrate the cell membrane, 
i.e. the inorganic nanoparticles (calcium phosphate) are necessary as carriers to 
enter the cell. 
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3.5 Functionalization of calcium phosphate nanoparticles by 
oligonucleotides and their application for gene silencing 
A promising approach for the treatment of inherited and acquired diseases are 
gene silencing techniques[191] which can selectively inhibit the synthesis of 
proteins in a cell. Short fragments of nucleic acids (DNA or RNA) with typical 
lengths of 15-30 nucleotides must be introduced into a cell[192-194]. These 
oligonucleotides are able to interact with the mRNA transcripts of a mutant or 
an over-expressed gene inside the cell (in the cytoplasm), thereby preventing 
their translation into disease-related proteins. 
The major challenge of this approach is to find an efficient delivery method 
system for oligonucleotides into the cell. Generally, oligonucleotides can only 
exert their inhibitory role when they have entered the cell[180], i.e. after passing 
through the cell membrane. Effective viral systems were developed to achieve 
this goal, but this approach is potentially dangerous due to the risk of 
recombination of the virus, strong immunogenicity and carcinogenicity[195]. 
Most alternative methods make use of the fact that nanoparticles are taken up by 
living cells, and can therefore be used as carriers for biomolecules like DNA, 
RNA, or oligonucleotides. Generally, the uptake of “naked” oligonucleotides or 
DNA into cells is not possible[73]; therefore a suitable carrier is needed. The 
problem with the non-viral delivery of oligonucleotides into cells in gene 
therapy is similar to the delivery of DNA. However, it may be assumed that 
short oligonucleotides are taken up easier than full-size DNA[196]. Generally, the 
uptake of "naked" oligonucleotides or DNA into cells is not possible[196]; 
therefore a suitable carrier is needed. A promising approach that has been 
developed in the last years is the use of nanoparticles as carriers for these 
biomolecules. Provided that the nanoparticles are small enough, different 
substances can be used, like polymers[197, 198], liposomes[199], peptides, or 
inorganic nanoparticles like silica[200, 201], magnetite[200, 201], gold[115, 202], and 
calcium phosphate[118, 154, 163]. 
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It was shown in previous chapters that custom-made DNA-functionalized 
calcium phosphate nanoparticles can be used for cell transfection. Calcium 
phosphate is advantageous to other types of nanoparticles due to its easy 
preparation (also inexpensive), its high affinity to DNA[203], its high 
biocompatibility, and its good biodegradability in biological systems[12]. In this 
chapter we report the preparation and stabilization of such nanoparticles with 
oligonucleotides of defined length and sequence. As proof of principle, we also 
show that double-stranded RNA (22 nucleotides) can induce gene-specific 
inhibition of the expression of enhanced green fluorescent protein (EGFP) in 
HeLa-EGFP cells. 
 
 
3.5.1 Characterization of calcium phosphate/oligonucleotide colloids  
Calcium phosphate nanoparticles were prepared by rapid mixing of aqueous 
solutions of calcium and phosphate (with the concentration 6.25 mM and 3.74 
mM), followed by addition of oligonucleotides to the formed dispersion to coat 
the inorganic nanoparticles and to prevent their aggregation. As with DNA, we 
expected the negatively charged oligonucleotides to interact with the calcium 
phosphate surface[203]. The high degree of adsorption can be immediately 
derived from the strongly negative zeta potential (pure calcium phosphate has a 
zeta potential of about +7 mV)[156]. The oligonucleotides on the surface should 
stabilize the dispersions both by electrostatic repulsion as well as by steric 
stabilization (Figure 3.5.1.1). 
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Table 3.5.1.1: Colloid-chemical data of oligonucleotide-functionalized calcium phosphate at 
a concentration of the oligonucleotides of 5 µM. 
 
Sample Oligo 5'-3' 
(single-stranded) 
Zeta 
potential / 
mV 
Size of small 
particles / nm 
Size of large 
particles / nm 
10-1  AGTCCCCTCT -2 578 >5000 
18-2  GGAGCTGGTGTTTACGGC -23 233 935 
18-3  GAGCCAACCTGGCTCTGA -14 - 1831 
25-5  
TTAGCCATGGGTGCACTT
GAGCGGC 
-25 176 516 
30-6  
CCCTGGATCCCATATGCT
ATTACCAGAACA 
-18 313 944 
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Figure 3.5.1.1: Schematic model of the interaction between a calcium phosphate particle and 
an oligonucleotide. 
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Figure 3.5.1.2: Results of dynamic light scattering of calcium phosphate nanoparticles, 
functionalized by single-stranded oligonucleotides (concentration 9 µM). The particles had an 
average size around 200 nm (solid line: sample A; dashed line: sample D; dotted line: sample 
F; Table 3.5.1.2). 
 
 
 
Figure 3.5.1.3: Scanning electron micrograph (SEM) of calcium phosphate nanoparticles, 
functionalized with the single-stranded oligonucleotide 25-G at a concentration 9 µM (Table 
3.5.1.2; sample C). Note that the particle size in SEM is smaller than by dynamic light 
scattering because in the latter method, the hydrodynamic radius is measured.
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Table 3.5.1.2: Colloid-chemical data of functionalized calcium phosphate nanoparticles (standard deviations given after the average in parantheses). 
The initial concentrations were [Ca2+]=6.25 mM and [HPO42-]=3.74 mM. PDI=Polydispersity index from dynamic light scattering. 
 
 Name Sequence (from 5' to 3') [Oligo] / µM Zeta potential / mV PDI Particle size (Z-average) / nm 
A 25-5 TTAGCCATGGGTGCACTTGAGCGGC 9 -29 (7) 0.3 212 
B 25-comp GCCGCTCAAGTGCAC CCATGGCTAA 9 -29 (6) 0.3 194 
C 25-G CGGTAGAGGGGACTTTCCGAGTGGC 9 -30 (8) 0.2 184 
D 25-C GCCACTCGGAAAGTCCCCTCTACCG 9 -28 (8) 0.3 202 
E 25-polyC CCCCCCCCCCCCCCCCCCCCCCCCC 9 -29 (6) 0.3 256 
F 37-V AGAGGGGACTTTCCGAGACGCTCGGAAAGTCCCCTCT 9 -29 (6) 0.3 210 
G 25-5 TTAGCCATGGGTGCACTTGAGCGGC 45 -44 (12) 0.5 437 
H 25-comp GCCGCTCAAGTGCAC CCATGGCTAA 45 -37 (8) 0.3 250 
I 25-G CGGTAGAGGGGACTTTCCGAGTGGC 45 -30 (10) 0.5 581 
J 25-C GCCACTCGGAAAGTCCCCTCTACCG 45 -36 (7) 0.3 271 
K 25-polyC CCCCCCCCCCCCCCCCCCCCCCCCC 45 -20 (7) 0.5 552 
L V-37 AGAGGGGACTTTCCGAGACGCTCGGAAAGTCCCCTCT 45 -31 (7) 0.4 237 
M 25-5/25-comp double strand of 25-5 and 25-comp 5 -22 (7) 0.2 352 
N 25-5/25-comp double strand of 25-5 and 25-comp 9 -21 (5) 0.3 297 
O 25-5/25-comp double strand of 25-5 and 25-comp 45 -33 (10) 0.2 113 
P 25-G/25-C double strand of 25-G and 25-C 5 -22 (7) 0.2 307 
Q 25-G/25-C double strand of 25-G and 25-C 9 -20 (6) 0.4 367 
R 25-G/25-C double strand of 25-G and 25-C 45 -36 (12) 0.3 231 
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A good colloidal stabilization of single-stranded oligonucleotides was possible 
at a concentration of 9 µM as shown by dynamic light scattering and electron 
microscopy (Figures 3.5.1.2 and 3.5.1.3). At a lower concentration (5 µM), only 
larger aggregates were observed (>500 nm) (Table 3.5.1.1) and at a higher 
concentration (45 µM), also larger aggregates (>1000 nm) besides the 100-200 
nm particles were observed in some cases by dynamic light scattering (Table 
3.5.1.2).  
 
 
 
Figure 3.5.1.4: Scanning electron micrograph of calcium phosphate nanoparticles, 
functionalized with the single-stranded oligonucleotide 25-5 (A) and 25-5comp (B), 25-C (C), 
and 25-polyC (D) with the concentration 45 µM. (Table 3.5.1.2; samples G, H, J, K). 
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We assume that at the lower concentration, the surface was not sufficiently 
covered to prevent crystal growth, and that at the higher concentration, 
agglomeration of the primary particles occurred. This agglomeration may be 
driven by the interaction of complementary nucleobases. 
At the optimal concentration (9 µM), we observed no significant differences in 
particle size (around 200 nm) and zeta potential (around -30 mV) for the 
different single-stranded oligonucleotides. However, the sequence and ratio of 
the nucleobases in the single-stranded oligonucleotides had an influence on the 
particle size at the higher concentration (45 µM). A strong tendency to 
agglomeration was observed for the oligonucleotides 25-5, 25-G, 25-polyC 
where the particle size reached 400-500 nm. However, the change in size was 
not significant for the other oligonucleotides (Table 3.5.1.2).  
 
 
 
Figure 3.5.1.5: Transmission electron micrograph of calcium phosphate nanoparticles, 
functionalized by the oligonucleotide 25-G with the concentration 45 µM. The particles had a 
typical size around 70 nm (Table 3.5.1.2; sample I). 
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Electron microscopy revealed that the larger particles at the higher concentration 
(45 µM) consisted of agglomerated primary nanoparticles and not of large 
individual crystals (Figures 3.5.1.4 and 3.5.1.5). This supports the assumption 
that the oligonucleotides effectively prevented the crystal growth, but also 
caused some kind of bridging of neighboring particles. 
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 Figure 3.5.1.6: Results of dynamic light scattering of calcium phosphate nanoparticles, 
functionalized with double-stranded oligonucleotides at theconcentration 45 µM (solid line: 
25-G/25-C; dashed line: 25-5/25-comp). (Table 3.5.1.2; samples R, O). 
 
We used the same concentrations as for single-stranded oligonucleotides to 
stabilize calcium phosphate nanoparticles with double-stranded oligonucleotides 
(25-5/25-comp and 25-G/25-C). In this case, a higher concentration was needed 
for effective stabilization. The optimal concentration was 45 µM with a particle 
size around 110 nm for 25-5/25-comp and 230 nm for 25-G/25-C (Figure 
3.5.1.6). The concentrations of 5 µM and 9 µM are too small for an effective 
stabilization, and the particles showed an increase in the hydrodynamic diameter 
up to 350 nm (Table 3.5.1.2). 
In this case not only the concentration of double-stranded oligonucleotides but 
also the type of oligonucleotides played an important role in the formation of 
nanoparticles. As shown in Figure 3.5.1.7, calcium phosphate nanoparticles 
functionalized by double-stranded oligonucleotides had a different size and 
morphology. 
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Figure 3.5.1.7: Scanning electron micrograph of calcium phosphate nanoparticles, 
functionalized with the double-stranded oligonucleotides 25-5/25-comp and 25-G/25-C 
(Table 3.5.1.2, samples O, R). 
 
Colloids with the 25-5/25-comp duplex consisted of spherical smooth 
nanoparticles with hydrodynamic diameters of about 110 nm. On the other hand, 
the double-stranded oligonucleotides 25-G/25-C with calcium phosphate formed 
fluffy nanoparticles with a size of 230 nm (Figure 3.5.1.7, Table 3.5.1.2). In the 
latter case, the growth of the calcium phosphate nanocrystals was not effectively 
inhibited. 
 
 
3.5.2. Gene silencing experiments on HeLa-EGFP cells 
Gene silencing was tested according to Refs[93, 204-206] on EGFP-HeLa cells with 
double-stranded siRNA, encoding the inhibition of EGFP synthesis. siRNA with 
22 nucleobases (22-nt) was shown earlier to induce the greatest decrease in GFP 
expression[93]. We used a concentration of 45 µM dsRNA which was found 
optimal for double-stranded oligonucleotides (see above). The resulting calcium 
phosphate/siRNA nanoparticles also had a particle size around 100 nm and a 
spherical morphology (Figure 3.5.2.1). siRNA was used to down-regulate the 
expression of an EGFP reporter pre-mRNA which is stably expressed in HeLa 
cells. Once the mRNA has been cleaved, the synthesis of the fluorescing protein 
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EGFP cannot occur anymore. Thus, the extent of EGFP inhibition in the cells 
(cells which show no green fluorescence anymore) is proportional to the 
antisense activity of the tested delivery system.  
The efficiency can then be easily computed from the ratio of still fluorescing 
cells to the total number of cells. Figure 3.5.2.2 and Table 3.5.2.1 show the 
corresponding results. The efficiency of gene silencing was between 40 and 60 
%, with no significant dependence on the medium. The efficiency of the 
dispersion did not decrease after two weeks of storage at 4 °C, indicating a high 
stability of the colloidal dispersions. The results of EGFP knockdown efficiency 
of HeLa-EGFP in DMEM with FCS and in Quantum® medium are graphically 
represented in Figure 3.5.2.3 
Note that such calcium phosphate nanoparticles are not toxic as shown earlier by 
Welzel et al. by an MTT test[154]. In addition, the morphology of the cells in light 
microscopy showed that they were still alive, therefore it cannot be argued that 
the decrease in the number of green fluorescing cells was due to an adverse 
action of the nanoparticles. The kind of cell culture medium did not play a 
significant role. 
 
 
 
Figure 3.5.2.1: Scanning electron micrograph of calcium phosphate nanoparticles, 
functionalized by siRNA (concentration 45 µM). 
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Figure 3.5.2.2: Transmission light microscopy (top row) and EGFP fluorescence microscopy 
(center and bottom rows; different contrast) of HeLa-EGFP antisense experiments after 
transfection. In the two upper rows, all cells can be seen. In the two lower rows, the cells 
which still express EGFP appear green. A: Control (no transfection); B: Cell culture in 
DMEM medium with FCS; C: Cell culture in Quantum® medium (magnification 200x in all 
cases). 
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 Table 3.5.2.1: Results of transfection experiments with HeLa-EGFP by numerical analysis of the laser fluorescence micrographs. The percentage 
of green fluorescing cells is given as average ± standard deviation (N=3 for freshly prepared dispersions; N=1 for dispersions stored at 4 °C). There 
is no significant decrease in the transfection efficiency after storage. 
 
Method Percentage of green 
fluorescing cells 
Percentage of not 
fluorescing cells 
Percentage of successful 
gene silencing 
Efficiency of gene 
silencing 
Control 82±4 % 100–82 = 18 % 18–18 = 0 % 0/82 = 0.00 
Calcium phosphate/oligo-nucleotide 
nanoparticles in DMEM/FCS, freshly 
prepared 
 
48±13 % 
 
100–48 = 52 % 
 
52–18 = 34 % 
 
34/82 = 0.41 
Calcium phosphate/oligo-nucleotide 
nanoparticles in DMEM/FCS, after 14 d 
storage at 4 °C 
 
40 % 
 
100–40 = 60 % 
 
60–18 = 42 % 
 
42/82 = 0.51 
Calcium phosphate/oligo-nucleotide 
nanoparticles in Quantum®, freshly 
prepared 
 
38±12 % 
 
100–38 = 62 % 
 
62–18 = 44 % 
 
44/82 = 0.54 
Calcium phosphate/oligo-nucleotide 
nanoparticles in Quantum®, after 14 d 
storage at 4 °C 
 
34 % 
 
100–34 = 66 % 
 
66–18 = 48 % 
 
48/82 = 0.59 
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Figure 3.5.2.3: EGFP knockdown efficiency of HeLa-EGFP in DMEM with FCS and in 
Quantum® medium, expressed as the ratio of the number of not fluorescing cells to the total 
number of cells with not transfected cells as control. The error bars represent the standard 
deviation (N=3). There were significant statistical differences between the transfection 
experiments and the control (P<0.001).  
 
Calcium phosphate nanoparticles as oligonucleotide delivery system have 
several advantages over other non-viral and viral delivery system. Such 
nanoparticles can be easily and cost-efficiently prepared, they are highly 
biocompatible and not cytotoxic, and they are not infectious like viral vectors. 
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3.5.3 Conclusion  
In the current study, we have shown the preparation of stable calcium 
phosphate/oligonucleotide dispersions and their biological application in vitro to 
HeLa-EGFP cells. Calcium phosphate nanoparticles can be stabilized with a 
shell of oligonucleotides. To obtain a stable colloid, both the oligonucleotide 
concentration and the nature of oligonucleotides (single- or double-stranded) 
must be considered. Monodisperse colloids could be prepared with single-
stranded oligonucleotides at a concentration of 9 µM and with double-stranded 
oligonucleotides at a concentration of 45 µM. The size of the stabilized 
nanoparticles is in the range of 100 nm, i.e. well-suited for cellular uptake. The 
dispersions showed a good physicochemical stability and could be stored at 4°C 
without agglomeration or precipitation for several weeks. 
We have developed this into a delivery system for antisense oligonucleotides in 
which these nanoparticles are used for down-regulation of gene expression by 
targeting the mRNA resulting in effective gene silencing. The 
nanoparticle/siRNA dispersions can be stored without loss of biological 
efficiency. 
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3.6 Synthesis of carbonated apatite with the model protein 
ubiquitin by the co-precipitation method 
Bone tissue is one of the most frequently used tissues for transplantation, as 
damage of bone can occur by various reasons such as trauma, tumor resection 
and others. 
Autogeneous, allogeneous and xenogeneous bone graft materials are used in 
clinical applications. Many complications like infection, pain, loss of sensibility 
and hematoma were described for these materials[207]. Synthetic calcium 
phosphate materials are currently under investigation for their potential as a 
bone-substitution material. Their chemical composition is similar to that of 
natural bone mineral, and they possess suitable biological properties like 
biocompatibility, osteoconductivity and biodegradability[159, 208-210]. 
Besides the scaffold material, another important component in bone regeneration 
are osteoinductive factors like bone morphogenetic proteins (BMP)[211]. BMPs 
play a key role in bone development and osteogenesis. 14 different BMPs are 
known, which belong to the transforming-growth-factor-beta (TGF-β) 
superfamily[212, 213]. The application of recombinant human bone morphogenetic 
protein 2 (rhBMP-2) is of great medical interest, because it leads to enhanced 
bone growth[214]. 
For our studies we have used the model protein ubiquitin which has been shown 
earlier to possess very similar adsorption properties like rhBMP-2[215, 216]. 
Here we studied the way to load a nanocrystalline calcium phosphate with the 
model protein ubiquitin at pH 10 and room temperature. In the first part, we 
studied the influence of ubiquitin on the formation and properties of the formed 
carbonated apatite by comparing ubiquitin-calcium phosphate samples (co-
precipitation method) and calcium phosphate samples without ubiquitin (see 
chapter 4.5.6).  
In the second part, we determined how much of the radioactive ubiquitin was 
incorporated into the calcium phosphate particles by the co-precipitation method 
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compared to the control ubiquitin-calcium phosphate samples where the 
formation of calcium phosphate particles occurred first, followed by the addition 
of ubiquitin. 
 
 
 
Figure 3.6.1.1: Schematic setup of the apparatus used for the preparation of the ubiquitin-
calcium phosphate samples by the co-precipitation method. I: Ca2+-solution and PO43-/CO32- 
were mixed in a vessel containing 5 mg of ubiquitin solution to form a precipitate. II: The 
dispersion stood for 5 hours. III: The dispersion was washed and filtered off. The powder was 
dried for 12 h at 37 °C. 
 
 
3.6.1 Characterization of the ubiquitin-calcium phosphate samples 
Two types of the samples were used for the characterization: Ubiquitin-calcium 
phosphate samples prepared by the co-precipitation method and calcium 
phosphate samples prepared without ubiquitin. 
Calcium phosphate particles prepared without ubiquitin are different in shape 
compared to those obtained in the presence of ubiquitin. Figure 3.6.1.2 (A, B) 
shows SEM images of the calcium phosphate powder without ubiquitin. The 
crystals were approximately spherical with a diameter around 50-80 nm. 
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Ubiquitin molecules presented during precipitation slightly affected the 
morphology and size of the particles.  
 
 
 
Figure 3.6.1.2: Scanning electron micrograph of calcium phosphate samples without 
ubiquitin (A, B) and the ubiquitin-calcium phosphate samples prepared by the co-precipitation 
method (C, D). 
 
As represented in Figure 3.6.1.2 (C, D), the particles prepared by the co-
precipitation method with ubiquitin were aggregated and showed no defined 
form.  
It is important to note that ubiquitin led only to a slight change in the structural 
properties of the nanocrystalline calcium phosphate phase. In Figure 3.6.1.3 the 
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infrared spectra are shown, recorded for co-precipitated ubiquitin-calcium 
phosphate samples and for calcium phosphate samples without ubiquitin. 
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Figure 3.6.1.3: Infrared spectra of calcium phosphate samples without ubiquitin and the 
ubiquitin-calcium phosphate samples prepared by the co-precipitation method.  
 
 
Infrared spectroscopy (IR) showed that in both cases infrared absorption bands 
are typical for calcium phosphate (Figure 3.6.1.3). The presence of calcium, 
phosphate and oxygen was shown by EDX analysis (Figure 3.6.1.4). 
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Figure 3.6.1.4: EDX of calcium phosphate samples without ubiquitin (dashed line) and the 
ubiquitin-calcium phosphate samples prepared by the co-precipitation method (solid line). 
 
Powder X-ray diffraction (XRD) was applied to identify the nanocrystalline 
structure of calcium phosphate. Figure 3.6.1.5 displays the XRD pattern for the 
powder corresponding to Figure 3.6.1.2. A difference was observed between 
calcium phosphate and ubiquitin-calcium phosphate materials. The samples co-
precipitated with ubiquitin showed a higher crystallinity than the control 
samples prepared without ubiquitin, as indicated by narrower diffraction peaks.  
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Figure 3.6.1.5: X-ray powder diffractogram of calcium phosphate samples without ubiquitin 
(A) and the ubiquitin-calcium phosphate samples prepared by the co-precipitation method 
(B).  
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The properties of calcium phosphate in the presence of biologically active 
molecules (osteogenic agents, growth factors, drugs, etc.) were extensively 
studied earlier[217-220]. The adsorption of proteins onto HA is of interest because 
the understanding of the interaction between proteins and HA is fundamental for 
an understanding of biomineralization. Miles et al. reported organic materials 
which affected the formation of biological apatite[221]. Termine et al. closer 
investigated the influence of various macromolecules on HA in solution and 
showed that biomolecules restrained the crystal growth of HA, and in some 
cases completely inhibited the transformation of ACP to HA[222]. 
Bernardi et al. showed that at a given pH some proteins bind to the calcium sites 
on the surface of HA crystals by negatively charged acidic groups and that more 
basic proteins attach to surface phosphate groups[223]. 
Numerous reports have shown that proteins and peptides which have a high 
negative charge inhibited the nucleation and crystal growth of HA[224-226].  
In our case we showed that ubiquitin had a only a small influence on the 
formation of the calcium phosphate. 
 
 
3.6.2 Measurement of the incorporation of radioactive ubiquitin into the 
particles 
The percentage of incorporated radioactive ubiquitin into the nanoparticles was 
measured with a γ-counter in ubiquitin-calcium phosphate samples prepared by 
the co-precipitation method and in control samples. 
By the co-precipitation method (Figure 3.6.1.1), 2.081 g of dry ubiquitin-
calcium phosphate powder were obtained from 3 L of solution. The 
concentration of ubiquitin after mixing was 5 µg mL-1 which corresponded to 
15000 µg ubiquitin in 3 L of the calcium phosphate dispersion. For a calibration 
curve, 6 samples (1 mL each) were taken from the ubiquitin-calcium phosphate 
dispersion and measured on the γ-counter (Table 3.6.2.1).  
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Table 3.6.2.1: Results of the calibration samples for ubiquitin-calcium phosphate prepared by 
the co-precipitation method.  
 
Sample counts per minute (cpm) 
1 44577.2 
2 46175.5 
3 46219.9 
4 46278.8 
5 45563.3 
6 46152.0 
 
The average was 45828 cpm corresponding to 5 µg ubiquitin. Therefore, 1 µg of 
ubiquitin corresponded to 9166 cpm. 
Then 3 samples of ubiquitin-calcium phosphate powder with the mass of     
0.141 g, 0.066 g and 0.112 g were taken and measured. It was found that these 
samples contained 63.7 µg, 33.2 µg and 53.3 µg of ubiquitin, respectively. 
Finally, the mass of ubiquitin in 1 g of ubiquitin-calcium phosphate powder was 
calculated (Table 3.6.2.2, samples 1A-3A) 
The total mass of ubiquitin-calcium phosphate (2.081 g) contained 993 µg of 
ubiquitin. Therefore, the percentage of incorporated ubiquitin was: 993 / 15000 · 
100 % = 6.6 %. 
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Table 3.6.2.2: Results of γ-Counter for the calculation of ubiquitin contents in the calcium 
phosphate powder. Samples A series show the results of co-precipitation and B series show 
the control experiment.  
 
Sample CaP / g cmp Ubiquitin / 
µg 
µg Ubiquitin / 
g Ubiquitin-
CaP 
Average 
µg Ubiquitin / 
g Ubiquitin-CaP
1A 0.141 584404.1 63.7 452.2 
2A 0.066 304324.3 33.2 503.0 
3A 0.112 488639.7 53.3 476.0 
 
477 
1B 0.078 131658.5 13.07 167.6 
2B 0.049 92010.5 9.14 186.5 
3B 0.054 94267.2 9.36 173.3 
 
176 
 
In the same way the bound ubiquitin was determined in the control samples. As 
control was prepared and dried without ubiquitin and then dispersed in a 
solution of radioactive ubiquitin. Thus, only the surface was coated. The final 
concentration of ubiquitin was the same as in the co-precipitation method (5 µg 
mL-1). 6 samples (1 mL each) were taken from the ubiquitin-calcium phosphate 
dispersion and measured on the γ-counter (Table 3.6.2.3).  
 
Table 3.6.2.3: Results of the calibration samples for control ubiquitin-calcium phosphate 
samples.  
 
Sample counts per minute (cpm) 
1 51498.3 
2 51855.9 
3 50877.7 
4 49869.1 
5 49057.8 
6 48839.5 
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The average is 50333 cpm corresponding to 5 µg ubiquitin. Therefore, 1 µg of 
ubiquitin corresponded to 10067 cpm. 
Then 3 samples with the following masses 0.078 g, 0.049 g, 0.0540 g were taken 
from control ubiquitin-calcium phosphate powder and measured. Finally the 
following masses of ubiquitin were determined (13.07 µg, 9.14 µg and 9.36 µg) 
and calculated for 1 g of ubiquitin-calcium phosphate powder (Table 3.6.2.2, 
samples 1B-3B). The total mass of ubiquitin-calcium phosphate (2.006 g) 
contains 353 µg of ubiquitin. The percentage of bound ubiquitin was: 353 / 
15000 · 100 % = 2.35 %.  
 
We found that the total percentage of bound ubiquitin after co-precipitation was 
6.6 % which included the protein adsorbed on the surface as well as that 
incorporated into the crystals. In the control experiments 2.35 % of ubiquitin 
was found on the surface of the crystals. In this case ubiquitin could only be 
adsorbed on the surface of calcium phosphate particles, because formation of 
calcium phosphate particles took place without the presence of ubiquitin. The 
difference between the total amount of ubiquitin (adsorbed and incorporated) 
and that adsorbed on the surface (from control samples) was 4.25 %. That means 
that about 4.25 % of ubiquitin were incorporated into the crystals. 
The amount of incorporated 125I-ubiquitin strongly depended on the way of 
precipitation and ubiquitin incorporated into the calcium phosphate particles 
three times better when the formation of crystals occurred in the presence of 
ubiquitin, i.e. by co-precipitation. 
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3.6.3 Conclusion 
We performed the preparation of calcium phosphate samples with ubiquitin by 
the co-precipitation method.  In these experiments ubiquitin served as a model 
protein, which has similar immobilization properties as rhBMP-2. We showed 
that the presence of ubiquitin had almost no influence on the crystallinity and 
crystal morphology. 
It was demonstrated that up to 6.6 % of 125I-ubiquitin can be 
adsorbed/incorporated into the particles and 4.25 % of the protein was 
incorporated.  
The presented co-precipitation method allows the preparation of calcium 
phosphate particles loaded with proteins similar to ubiquitin. It means that 
proteins of the BMP family are able to adsorb on the calcium phosphate 
particles. An implantation of such biofunctionalized calcium phosphate ceramics 
(e.g. cold-isostatically pressed into an appropriate shape) in bone defects can 
stimulate the development of new bone at the implantation site.  
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4 Materials and Methods 
4.1 Applied materials for cell culture experiments 
4.1.1 Cell culture solutions/antibiotics  
Accutase PAA 
BM Cyclin 1 + 2 Roche 
DMEM PAA 
FCS PAA, Biochrom 
Glutamine Gibco BRL/Invitrogen 
HEPES Biomol 
PBS Biochrom 
Penicillin/Streptomycin Gibco BRL/Invitrogen, PAA 
Quantum®  PAA 
RPMI1640 PAA, Biochrom 
Trypsine Gibco BRL/Invitrogen 
 
 
4.1.2 Chemicals  
Ampicillin Biomol 
EDTA Merck 
Ethanol JT Baker 
Ethidium bromide Serva 
Glycerol Riedel de Haen 
Yeast-extract Roth 
Pepton-hydrolysate Gibco BRL 
SDS Biomol 
 
 
4.1.3 Devices  
Incubator Heraeus 
Microscopes Olympus CK2 
Olympus IX51 
Zeiss Axioplan 
Zeiss Axiovert 35 
Laminar flow hood Heraeus  
Thermomixer Eppendorf  
Centrifuges Eppendorf 5415C (Minifuge) 
Heraeus Megafuge 1.0R  
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4.1.4 Applied consumables und kits 
Nucleobond® PC 10000 plasmid DNA 
purification kit (endotoxin-free) 
Macherey-Nagel 
multi plate wells (24-, 6-wells) Nunc, TPP, Sarstedt 
Polyfect® Qiagen, Hilden 
Flasks 75 cm3 Nunc, TPP 
 
4.2 Molecular-biological methods 
 
4.2.1 Preparation of plasmid-DNA from bacterial culture 
All works with intact bacteria were carried out under semi-sterile conditions 
with autoclaved instruments and solutions[227]. 
 
4.2.1.2 Transformation of bacteria  
250 µl of competent bacteria were thawed from -80 °C and placed on ice. 5 µl of 
ligation sequences was added and the mixture was incubated on ice for about 30 
min. A heat shock was carried out in the thermoblock for 90 s at 42 °C, 
afterwards 1 mL LB (Luria Bertani) medium was added and incubated for 30 
min at 37 °C. 
Then the bacteria were centrifuged (Minifuge, 3000 rpm, room temperature, 2 
min), smoothed out on LB-ampicillin-plates and then incubated at 37 °C up to 
12 h until visible colonies of bacteria appeared[228]. 
Permanent cultures of transformed bacteria were taken from overnight cultures, 
placed with 50 % of glycerol and stored at -80 °C. 
 
LB medium: 
10 g L-1 Pepton-hydrolysate 
10 g L-1 NaCl 
5 g L-1 yeast-extract 
pH 7.4 with NaOH 
+ 100 µg ml-1 ampicillin 
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4.2.1.3 Preparation of plasmid-DNA for transfection of eukaryotic cells 
The preparation of plasmid-DNA for transfection of eukaryotic cells was 
accomplished with a NucleoBond® PC 10000 EF kit (Macherey-Nagel, Düren). 
Sterile plasticware and autoclaved glassware were used. 100 mL LB-ampicillin-
medium was mixed with a bacterial culture and incubated over night under 
shaking at 37 °C. The bacteria were centrifuged in 50-ml-tubes (Megafuge, 
4000 rpm / 3200 g, 15 min, 4 °C). The purification of plasmid-DNA was carried 
out according to the manufacturer’s recommendation (Nucleobond PC 1000 
plasmid DNA, Macherey-Nagel). After the precipitation of DNA and washing 
the DNA precipitates, plasmid-DNA was placed in sterile endotoxin-free water. 
The concentration was determined by UV-photometry and the DNA was stored 
at -20 °C. 
 
 
4.2.2 Synthesis of oligonucleotides 
All oligonucleotides were assembled in A. N. Belozersky Institute of Physico-
Chemical Biology, M. V. Lomonosov Moscow State University, on an ABI 
394A DNA Synthesizer by the cyanoethyl phosphoramidite method according to 
the manufacturer's recommendations and purified by reversed-phase HPLC. The 
conditions of reversed-phase HPLC were as follows: Reversed-phase HPLC 
(Tracor) on a DIAKS-130-CETYL column (4·250 mm); buffer A: 0.1 M 
ammonium acetate (pH 7); buffer B: 0.1 M ammonium acetate, 40 % MeCN 
(pH 7); gradient of B from 0 to 100 % in 60 min; flow rate 1 mL min-1; 
temperature 45 °C. 
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4.2.3 Fluorescence microscopy 
The fluorescence microscopy of EGFP-expressing cells was accomplished by 
inverse microscope on unfixed cells in cell culture vessels with a suitable 
fluorescence filter.  
 
4.3. Cell culture methods 
All cell culture work was carried out with sterile solutions and devices in a 
laminar-flow workbench. For the experiments with and without serum the same 
protocol was used. 
 
 
4.3.1 Cultivation of secondary cell lines 
T-HUVEC were cultivated in bicarbonate-buffered RPMI 1640 with 10 % FCS, 
2 mM glutamine, 100 U mL-1 penicillin and 100 U mL-1 streptomycin (culture 
medium) at 37 °C and in water-saturated atmosphere with 5 % CO2.  
Cells with confluence of 70-100 % were washed twice with PBS, then diluted 
with 0.25 % trypsine and with the medium consisting FCS (for trypsine 
inhibition). After centrifugation of the cells (Biofuge, 900 rpm / 160 g, 5 min, 
room temperature) the supernatant with trypsine was removed, the cells were 
resuspended in fresh medium and placed an adequate dilution into new 75 cm3-
flask. The cell density of the suspension was determined by counting in a 
Neubauer's counting chamber. 
 
T-HUVEC culture medium: 
RPMI 1640 
10 % FCS 
2 mM glutamine 
100 U mL-1 penicillin  
100 U mL-1  streptomycin 
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4.3.2 Cryoconservation and defrosting of cells 
For cryoconservation the cells were washed with PBS, trypsinised and 
centrifuged. Then they were resuspended in 1 mL FCS with 7.5 % DMSO 
(Dimethyl sulfoxide) and replaced into a cryotube. After they were slowly 
cooled down during more than 24 h to 80 °C and kept in liquid nitrogen. 
The cells were defrosted in a short period of time to 37 °C. To avoid an osmotic 
shock during the first 5 min, 5 mL FCS was added, the cells were centrifuged 
(Biofuge, 900rpm / 160 g, 5 min, room temperature), and dissolved in fresh cell 
culture medium. After 24 h, the medium was changed to eliminate the rests of 
DMSO. 
 
 
4.3.3 Cell transfection  
The cells were cultured in RPMI 1640 medium (T-HUVEC) or in DMEM 
(HeLa and LTK), supplemented with 10 % fetal calf serum (FCS) at 37 °C and 5 
% CO2 (T-HUVEC) or 10 % CO2 (Hela, LTK) and subcultivated according to 
standard cell culture protocols. One day before the transfection, the cells were 
trypsinised and seeded in cell culture dishes with 2·104 cells per 24-well dish 
resulting in a cell density of 104 cells cm-2. For transfection, Quantum® medium 
without FCS was also used. Quantum® medium is based on modified RPMI and 
supplemented with selected fractions of serum components and protein extracts 
from yeast.  
A plasmid DNA, pcDNA3-EGFP, coding for the fluorophor protein EGFP 
(enhanced green fluorescent protein) was purified from E. coli using 
Nucleobond® endotoxin-free plasmid DNA (Macherey-Nagel, Düren, 
Germany). 
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4.3.3.1 Transfection with Polyfect® 
Transfection with the dendrimer-based commercial agent Polyfect® (Qiagen, 
Hilden, Germany) was carried out according to the manufacturer’s 
recommendation: 2 µg DNA were dissolved in 100 µL medium without FCS to 
which 22 µL Polyfect®-solution was added. After mixing, the dispersion stood 
for 5 min, and then 600 µL cell culture medium were added. From the cell 
culture, the culture medium was replaced by 1.5 mL fresh medium and the 
transfection mixture was added. The transfection mixture remained on the cells 
for 7 h. 2 µg DNA were used per transfection. 
 
 
4.3.3.2 Standard calcium phosphate transfection 
The standard transfection with calcium phosphate was carried out as follows: 4 
µL aqueous solution containing 4 µg of DNA were mixed with 10 µL of 2.5 M 
CaCl2 solution. The dispersion was left to stand for 5 min. The volume of the 
dispersion was adjusted to 100 µL with water and 100 µL HEPES buffered 
saline solution (2 · HBS: 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4, 12 mM 
dextrose, 50 mM HEPES, pH=7.05 ± 0.01) were added. Cell culture medium 
(RPMI 1640 with and without FCS, or Quantum®) was added up to 1 mL. From 
the cell culture, the culture medium was removed with a syringe and the 
transfection mixture was added. The duration of the transfection was 7 h. 4 µg 
DNA were used per transfection. 
 
4.3.3.3 Transfection with custom-made calcium phosphate nanoparticles 
The custom-made calcium phosphate nanoparticles were used for transfection as 
follows: 20 µL of calcium phosphate/DNA nanoparticles dispersion (prepared as 
shown in Figure 3.1.2.1.) were thoroughly mixed with 1 mL medium (RPMI 
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1640 with/without FCS for T-HUVEC, DMEM with/without FCS for HeLa and 
LTK, or Quantum® for T-HUVEC, HeLa, and LTK). From the cell culture, the 
cell culture medium was removed and 1.0 mL of the transfection mixture was 
added. The duration of transfection was 7 h.  
4.3.3.4 Calculation of transfection efficiency 
The efficiency of the transfection was studied by transmission light microscopy 
and by fluorescence microscopy using an IX51 microscope (Olympus, 
Hamburg, Germany). A successful transfection was detected by fluorescence 
microscopy at a magnification of 200x where the encoded fluorophor protein 
EGFP (enhanced green fluorescent protein) was excited, and counting the cells. 
Only when pcDNA3-EGFP was successfully incorporated into the nuclear 
DNA, the synthesis of the fluorophor protein EGFP occurred and these cells 
showed the green fluorescence of this protein. The transfection efficiency was 
computed by the ratio of cells in which EGFP was expressed to the total 
examined number of cells. 
 
 
4.3.4 Transport of nanoparticles into the cells 
T-HUVEC (transformed human umbilical vein endothelial cells) were cultured 
in RPMI 1640 medium, supplemented with 10 % fetal calf serum (FCS) at 37 °C 
and 5 % CO2 (T-HUVEC) and subcultivated according to standard cell culture 
protocols. 12 hours prior to transfection, the cells were trypsinised and seeded in 
cell culture dishes with 2·104 cells per 24-well dish (density 104 cells cm-2).  
Plasmid DNA (pcDNA3-EGFP) coding for the fluorophor protein EGFP 
(enhanced green fluorescent protein) was purified from E. coli using 
Nucleobond® endotoxin-free plasmid DNA (Macherey-Nagel, Düren, 
Germany). 
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The transfection with the three types of nanoparticles was carried out as 
follows[163]: 20 µL of the particle dispersion  was thoroughly mixed with 1 mL 
RPMI 1640 with FCS. From the cell culture, the cell culture medium was 
removed and 1.0 mL of the transfection mixture was added. The cells were 
transfected for 1 h, 2 h, and 4 h, followed by removal of the medium with the 
colloids. In the following set of experiments, the duration of transfection was 7 
h, then the colloidal dispersion with the medium was removed and replaced by 1 
mL of fresh medium. Therefore, only nanoparticles which were either taken up 
by the cells or strongly adsorbed on the cellular surface remained. Additional 
samples were taken after 1h (total: 8 h), 17 h (total: 24 h), and 41 h (total: 48 h). 
Immediately after the indicated time the cells were washed three times with PBS 
(phosphate buffered saline) to remove all dispersed nanoparticles (i.e. those 
neither taken up by cells nor adsorbed on cell membranes) and studied by 
microscopy. Fluorescence microscopy was carried out with an IX51 microscope 
(Olympus, Hamburg, Germany) and a Leica TCF SP2 laser confocal 
microscope. A successful incorporation of DNA into the nucleus was indirectly 
proven by fluorescence microscopy at a magnification of 200x where EGFP was 
excited. Only when pcDNA3-EGFP was successfully incorporated into the 
nuclear DNA, the synthesis of the fluorophor protein EGFP occurred and these 
cells showed the green fluorescence of this protein. 
 
 
4.3.5 Gene silencing experiments 
HeLa-EGFP (genetically modified human transformed cervix epithelial cells 
expressing enhanced green fluorescent protein; EGFP) were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 % fetal 
calf serum (FCS) and antibiotic G418-sulfate, with the final concentration in 
medium of 50 µg mL-1 at 37 °C under 10 % CO2 atmosphere. Cells were seeded 
in 24-well plates one day prior to transfection with 2·104 cells per plate resulting 
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in a cell density of 104 cells cm-2. Quantum® medium without FCS was also 
used. A desalted double-stranded RNA oligonucleotide (EGFP 22-nt[204]) was 
obtained from Invitrogen (Paisley, UK):  
Sense, 5’-GCAAGCUGACCCUGAAGUUCAU-3’;  
antisense, 5’-AUGAACUUCAGGGUCAGCUUGC-3’.  
The calcium phosphate nanoparticles were used for antisense as follows. 20 µL 
of calcium phosphate/oligonucleotide nanoparticle dispersion were thoroughly 
mixed with 1.0 mL medium (DMEM with FCS and Quantum®). From the cell 
culture, the cell culture medium was removed and replaced by 1.0 mL of the 
antisense mixture. The duration of transfection was 7 h. The experiments with 
freshly prepared nanoparticles were repeated three times each (N=3). The 
colloidal dispersions were also stored for 14 days at 4 °C and then used for 
transfection.  
The efficiency of the transfection was determined by fluorescence microscopy 
using an IX51 microscope (Olympus, Hamburg, Germany; magnification 200x). 
The numbers of green fluorescing cells and of non-fluorescing cells were 
manually counted. The transfection efficiency was computed as the ratio of cells 
in which EGFP was inhibited to the total number of cells. As control, HeLa-
EGFP cells cultured in DMEM with FCS medium was used. 
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4.4 Physicochemical methods 
4.4.1 Analytical ultracentrifugation 
The ultracentrifuge is a centrifuge optimized for spinning a rotor at very high 
speeds, capable of generating acceleration as high as 1000000 G (9800 km s-2) 
The sedimentation coefficient is measured in the unit Svedberg (S) where 1 S = 
10-13 s. S-distribution can be converted to the particle size distribution using the 
equation: 
 
 
where dH is the particle diameter, s is the sedimentation coefficient, η is the 
solvent viscosity, ρp is the particle density and ρs is the solvent density.  
This modified Svedberg equation applies a hard sphere approach and is only 
valid for solid particles. 
Ultracentrifugation was performed at 25 °C with an Optima XL-I (Beckman-
Coulter) with UV/Vis absorption and on-line Rayleigh Interference optics using 
the program SEDFIT for evaluation of the sedimentation coefficient 
distributions without diffusion correction and correction to infinite dilution at 
Max-Planck-Institute of Colloids and Interfaces in Golm. 
 
 
4.4.2 Dynamic light scattering (DLS) 
Dynamic light scattering is one of the methods used to determine the size of 
particles. The experiment’s theory is based essentially on two assumptions. The 
first assumption is that the particles are in Brownian motion. And the second one 
is that the particles observed in the experiment are spherical with a diameter 
small compared to the molecular dimensions.  
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Shining a monochromatic light beam onto a solution with spherical particles in 
Brownian motion causes a Doppler shift when the light hits the moving particle, 
changing the wavelength of the incoming light. This change is related to the size 
of the particle. It is possible to compute the sphere size distribution and give a 
description of the particle’s motion in the medium, measuring the diffusion 
coefficient of the particle: 
 
DT = kB T / 6 π ηRh  
 
where DT  is the translation diffusion coefficient, kB is the Boltzmann's constant, 
T is the temperature in Kelvin degrees, η is the viscosity of the solvent and Rh is 
the hydrodynamic radius. 
Since from the light scattering is possible to obtain information about the 
position of the particles, from the formulas above the radius of the particles is 
easy to get. 
Dynamic light scattering determinations were performed with a Zetasizer 
(NanoZS from Malvern instruments). 
 
 
4.4.3 Zeta potential measurements (ZP) 
The zeta potential is the electrical potential that exists at the Stern plane of a 
particle, which is at some small distance from its surface. The zeta potential is 
derived from measuring the mobility distribution of a dispersion of charged 
particles as they are subjected to an electric field. The mobility is defined as the 
velocity of a particle per electric field unit and is measured by applying an 
electric field to the dispersion of particles and measuring their average velocity. 
There are two approximations (by Hückel and by Smoluchowski) to obtain the 
zeta potential from the measured mobilities. The approximation by Hückel 
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applies to particles smaller than 10 nm. Because our particles were larger the 
model of Smoluchowski was used.  
 
Be = (ε ζ ƒb / η) (ω r2T ρ / η) 
 
Be: electrophoretic mobility 
ε: dielectric constant 
ζ: zeta potential 
η: viscosity 
ω: frequency of the electrical field 
r: radius of the particle 
ρ: density of the dispersion 
ƒb: correction factor 
 
The measurements for the computation of the zeta potential were carried out 
with a Malvern Zetasizer NanoZS. 
 
 
4.4.4 Infrared spectroscopy (IR) 
Infrared spectroscopy (IR Spectroscopy) is a type of absorption spectroscopy 
that uses the infrared part of the electromagnetic spectrum (wavelength 760 nm 
up to 500 µm). Infrared radiation does not trigger electronic excitation in 
substances but vibrational and/or rotational excitation. To be infrared active, a 
molecule must posses a dipole moment or must generate a dipole moment by 
vibration. The main modes of vibration are valence bond vibration, which is the 
atom vibration along a bond axis, and deformation vibration, which occur in 
molecules.  
Viktoriya Sokolova, Dissertation 2006 
 131
The energy in infrared spectra is usually given in wave numbers. The use of 
wave numbers offers the advantage of being directly proportional to the 
frequency of the absorbed radiation and thus the energy absorbed. 
Infrared spectroscopy deals with the interaction of infrared light with matter. 
The energy of an infrared photon can be calculated using the Planck energy 
relation 
 
∆E = h c υ 
 
with  E  the  absorbed  energy  in J,  h=6.626·10-34  J s Planck’s constant, 
c=3·1010 cm s-1 the speed of light and υ the wave number in cm-1. 
The rate of absorption of infrared energy depends mainly on the mass of the 
vibrating atoms. Detailed information about the infrared absorptions observed 
for various functional groups can be found in the literature. 
In this work examined samples were mixed with an about 200 fold excess of 
potassium bromide and pressed into pellets at 10 tons for 15 minutes. 
Measurements were carried out with a Perkin-Elmer 1720X instrument in 
transmission mode (resolution 2 cm-1, averaging of 10 scans). 
 
 
4.4.5 X-ray powder diffractometry (XRD) 
X-ray powder diffractometry allows the identification and quantification of 
crystalline phases. Each atom in crystal under the influence of X-rays scatters 
radiation and serves as the origin of a new wavefront. Wavefronts will interfere 
with one another either constructively or destructively, depending on the 
position of rays (in or out of phase). The occurrence of peaks depends on the 
constructive interference of the diffracted X-rays and is given by Bragg’s law: 
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2 · d sinΘ = n ·λ 
 
d: distance between scattering centers 
λ wavelength of the X-rays in Ǻ 
Θ the diffraction angle (angle between incident beam and scattering plane) 
n an integer value (n = 1, 2, 3 etc.) 
A STOE IP-PSD diffractometer with primary Ge(111) monochromator and half 
circle PSD was employed. All diffractograms shown in this work were measured 
with Cu Kα1-radiation (λ=1.54056 Ǻ), with 50 kV and 30 mA. 
 
 
4.4.6 Scanning electron microscopy (SEM) 
Classical microscopes are limited in resolution to the wavelength of visible light 
(400-750 nm). The scanning electron microscope (SEM) is a type of electron 
microscope capable of producing high-resolution images of a sample surface. 
With scanning electron microscopes, much smaller objects can be observed 
because high energy electrons are used for image creation.  
The accelerated electrons are focused by magnetic field lenses into a tight and 
narrow beam which scans an area of the sample. The diameter of the beam 
defines the maximum resolution of the instrument. The actual image observed is 
created by the secondary electron emissions of the scanned sample area. As 
electron emission from the surface is easier and more intense than from the 
inside of a sample, a contrast-rich 3 D-image is created. 
For SEM observation LEO S420 and ESEM Quanta 400 microscopes with 
palladium-sputtered samples were used. Additionally, an X-ray detector for 
energy dispersive X-ray analysis (EDX) permitted the detection of the elements 
present in the sample. 
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4.4.7 Transmission electron microscopy (TEM) 
The transmession electron microscope is an optical analogue to the conventional 
light microscope. It is based on the fact that electrons possess a wavelength but 
at the same time interact with magnetic fields as a point charge. A beam of 
electrons is applied instead of light, and the glass lenses are replaced by 
magnetic lenses. The lateral resolution can go down to a few Angstroms.  
A very thin slice of the tested material is exposed to a beam of electrons. By the 
interaction of electrons with consistent material structure, a constant fraction of 
electrons is transmitted through the sample to a detector. Once a structural 
imperfection is encountered, the fraction of transmitted electron changes. 
Transmission electron microscopy (TEM) was performed with a Philips CM 200 
FEG instrument on air-dried nanoparticles prepared on carbon-coated copper 
grids.  
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4.5 Experimental procedures 
4.5.1 The preparation of calcium phosphate/DNA colloids 
The preparation was performed as follows: An aqueous solution of calcium 
nitrate (6.25 mM or 18 mM) was mixed with an aqueous solution of 
diammonium or dipotassium hydrogen phosphate (3.74 mM or 10.8 mM). The 
pH of both solutions was adjusted beforehand to 9 with NaOH (0.1 M). Mixing 
was achieved by rapidly pumping both solutions into a glass vessel. After about 
30 s, 1 mL of the dispersion was taken with a syringe and rapidly mixed with 0.2 
or 1 mL of an aqueous solution of DNA (1 mg mL-1) in a polyethylene vessel 
(Figure 3.1.2.1).  
The substitution of calcium by magnesium or aluminum was accomplished by 
adding either magnesium nitrate or aluminum chloride to the calcium nitrate 
solution. 
The inorganic salts were all of p.a. quality. Ultrapure water (Purelab ultra 
instrument from ELGA) was used for all preparations. We used DNA (sodium 
salt) from salmon testes (16.2 A250 units mg-1 solid; 6.13 % Na) from Sigma for 
all experiments. 
 
 
4.5.2 Preparation of multi-shell nanoparticles  
Multi-shell nanoparticles were prepared as follows: First, DNA-coated calcium 
phosphate nanoparticles (so called single-shell) were prepared by mixing an 
aqueous solution of calcium nitrate (6.25 or 18 mM) with an aqueous solution of 
diammonium hydrogen phosphate (3.74 mM or 10.8 mM) at a pH 9. The 
calcium phosphate dispersion (1 mL) was taken with a syringe and rapidly 
mixed with 0.2 mL of an aqueous solution of DNA (1 mg mL-1) in a sterile 
Eppendorf tube (Figure 3.1.2.1). This dispersion had a final concentration of 167 
µg DNA mL-1 [163]. To form the outter calcium phosphate layer (double-shell 
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nanoparticles), we added 0.5 mL of calcium nitrate (6.25 or 18 mM) and then 
0.5 mL of diammonium hydrogen phosphate (3.74 mM or 10.8 mM). This 
resulted in a crystallization of calcium phosphate on the surface of the particles. 
A colloidal stabilization (to prevent aggregation of the calcium phosphate-
decorated surfaces) was then accomplished by adding 0.2 mL of DNA solution 
(1 mg mL-1) to form triple-shell nanoparticles. These dispersions had 
concentrations of 91 µg DNA mL-1 (double-shell) and 167 µg DNA mL-1 (triple-
shell).  
Welzel et al. showed by an MTT test that such calcium phosphate/DNA 
nanoparticles are not cytotoxic[154]. The amounts of DNA per transfection were 
3.3 µg (single-shell), 1.8 µg (double-shell), and 3.3 µg (triple-shell). 
 
 
4.5.3 Preparation of calcium phosphate/DNA/protamine nanoparticles  
DNA-coated calcium phosphate nanoparticles were prepared as follows: An 
aqueous solution of calcium nitrate (18 mM) was mixed with an aqueous 
solution of diammonium hydrogen phosphate (10.8 mM) (Figure 3.1.2.1). The 
pH of both solutions was adjusted beforehand to 9 with NaOH (0.1 M). Mixing 
was accomplished by rapidly pumping both solutions into a glass vessel. In 
parallel, DNA (1 mg mL-1) was pre-incubated with protamine at 1:1 volume-
ratio (0.2 mL DNA and 0.2 mL protamine). After about 30 s, 1 mL of the 
dispersion was taken with a syringe and rapidly mixed with 0.4 mL of an 
aqueous solution of DNA/protamine in a sterile Eppendorf tube. Different 
concentrations of protamine were used: 0.5, 1, 5, 10, 20 mg mL-1 so that the 
final concentrations of protamine in the calcium phosphate/DNA dispersion 
were 71 µg mL-1, 140 µg mL-1, 710 µg mL-1, 1430 µg mL-1 and 2860 µg mL-1. 
This dispersion had a final concentration of 140 µg DNA mL-1. 
Multi-shell nanoparticles were prepared as follows: First, DNA/protamine-
coated calcium phosphate nanoparticles were prepared as described above. To 
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this dispersion, we added 0.5 mL of calcium nitrate (18 mM) and then 0.5 mL of 
diammonium hydrogen phosphate (10.8 mM). This resulted in a crystallization 
of calcium phosphate on the surface of the particles. A colloidal stabilization 
was then accomplished by adding 0.4 mL of DNA/protamine solution. The 
concentration of DNA was always 1 mg mL-1. The final concentrations of 
protamine in the dispersion with double-shell nanoparticles were 40 µg mL-1, 80 
µg mL-1, 420 µg mL-1, 840 µg mL-1 and 1680 µg mL-1 and in the dispersion with 
triple-shell nanoparticles were 71 µg mL-1, 140 µg mL-1, 710 µg mL-1, 1430 µg 
mL-1 and 2860 µg mL-1. These dispersions had concentrations of 80 µg DNA 
mL-1 (double-shell) and 140 µg DNA mL-1 (triple-shell). The amounts of 
protamine per transfection were 1.4 µg, 2.8 µg, 14.2 µg, 28.6 µg, 57.2 µg 
(single- and triple-shell) and 0.8 µg, 1.6 µg, 8.4 µg, 16.8 µg, 33.6 µg (double-
shell). The amounts of DNA per transfection were 2.8 µg (single-shell), 1.6 µg 
(double-shell), and 2.8 µg (triple-shell). 
 
 
4.5.4 Preparation of nanoparticles with TRITC-BSA  
DNA-coated calcium phosphate nanoparticles were prepared as follows: An 
aqueous solution of calcium nitrate (18 mM) was mixed with an aqueous 
solution of diammonium hydrogen phosphate (10.8 mM). The pH of both 
solutions was adjusted beforehand to 9 with NaOH (0.1 M). Mixing was 
accomplished by rapidly pumping both solutions into a glass vessel. 
Three types of the nanoparticles were prepared. For calcium phosphate 
nanoparticles functionalized with red-fluorescing TRITC-BSA ("CaP/BSA"), 1 
mL of the calcium phosphate dispersion was taken with a syringe and rapidly 
mixed with 1 mL TRITC-BSA (1 mg mL-1). For calcium phosphate 
nanoparticles functionalized with both DNA and TRITC-BSA 
("CaP/DNA/BSA"), 1 mL of the calcium phosphate dispersion was taken with a 
syringe and rapidly mixed with 0.2 ml of pcDNA3-EGFP (1 mg mL-1) followed 
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by 1 mL TRITC-BSA (1 mg mL-1). The transfection ability of these particles 
was tested. DNA/BSA particles without a calcium phosphate core 
("DNA/BSA") were prepared as control: 1 mL of pcDNA3-EGFP solution (1 
mg mL-1) was mixed with 1 mL TRITC-BSA (1 mg mL-1). All samples were 
filtered with a sterile syringe filter with a 0.2 µm cellulose acetate membrane 
(VWR International) to remove larger aggregates.  
 
 
4.5.5 Preparation of calcium phosphate/oligonucleotide nanoparticles  
The calcium phosphate nanoparticles can be prepared reproducibly by mixing an 
aqueous solution of calcium nitrate (6.25 mM) with an aqueous solution of 
diammonium hydrogen phosphate (3.74 mM). The pH of both solutions was 
adjusted beforehand to 9 with NaOH (0.1 M). Mixing was achieved by rapidly 
pumping both solutions into a glass vessel. Immediately after mixing, 1.5 mL of 
the calcium phosphate dispersion was taken with a syringe and rapidly added to 
the 0.25 mL of an aqueous solution of oligonucleotides in a polyethylene vessel. 
Three different concentrations of the oligonucleotides were used: 35 µM, 63 µM 
and 320 µM so that the final concentration of oligonucleotides in the calcium 
phosphate dispersion was 5 µM, 9 µM and 45 µM, respectively (dilution 1:7). 
The samples were filtered through a sterile syringe with a 0.45 µm cellulose 
acetate membrane (Scheicher and Schuell) to remove larger aggregates. The 
inorganic salts were all of p.a. quality. Ultrapure water (Purelab ultra instrument 
from ELGA) was used for all preparations. Double-stranded oligonucleotides 
(25-5/25-comp and 25-G/25-C) were generated by mixing complimentary 
sequences of oligonucleotides in water, heating to 95 °C, and slowly cooling 
down to 4 °C. 
For gene silencing experiments with double-stranded small interfering RNA 
(siRNA), all calcium phosphate/siRNA dispersions were prepared in the same 
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way. The final concentration of dsRNA in the calcium phosphate dispersion was 
45 µM in all cases. This sample was not filtered to avoid adsorption on the filter. 
 
 
4.5.6 Preparation of the ubiquitin-calcium phosphate samples 
Carbonated apatite, which is comparable in chemical composition and 
crystallinity to bone mineral, was obtained by continuous fast precipitation in a 
crystallization setup. The preparation of three types of samples: 
I. Ubiquitin-calcium phosphate samples prepared by the co-precipitation 
method: Two solutions (18 mM [CH3CH(OH)COO]2Ca; 10.8 mM Na2CO3 + 
10.8 mM Na2HPO4) were continuously mixed in a glass vessel already 
containing 1 mL of the ubiquitin solution with a concentration 5 mg mL-1 to the 
final volume of 1 L (Figure 3.6.1.1, I). 2.081 g of dry ubiquitin-calcium 
phosphate powder were obtained from 3 L of solution. The concentration of 
ubiquitin after mixing was 5 µg mL-1 which corresponded to 15000 µg ubiquitin 
in 3 L of the calcium phosphate dispersion.  Radioactive ubiquitin was used only 
for γ-counter measurements, for all other analyses non-radioactive ubiquitin was 
used. The dispersion stood for 5 hours without stirring and then it was washed 5 
times with distilled water to remove adsorbed ubiquitin and filtered off (Figure 
3.6.1.1, II - III). The powder was dried under air at 37 °C for 12 hours. 
II. Calcium phosphate samples without ubiquitin: Two solutions (18 mM 
[CH3CH(OH)COO]2Ca; 10.8 mM Na2CO3 + 10.8 mM Na2HPO4) were 
continuously mixed in a glass vessel to the final volume of 1 L. Right after 
mixing, the dispersion was filtered off and dried under air at 37 °C for 12 hours. 
These samples were used for physicochemical analyses as a control. 
III. Control ubiquitin-calcium phosphate samples: Two solutions (18 mM 
[CH3CH(OH)COO]2Ca; 10.8 mM Na2CO3 + 10.8 mM Na2HPO4) were 
continuously mixed in a glass vessel to the final volume of 3 L. Right after 
mixing, the dispersion was filtered off and dried under air at 37 °C for 12 hours.  
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Then 2.006 g of nanocrystalline calcium phosphate powder, which corresponded 
to the mass of powder synthesized from 3 L dispersion, was redispersed in 3 L 
water, containing 15 mg of radioactive ubiquitin (final concentration 5 µg mL-1). 
The dispersion stood for 5 hours without stirring and then it was washed 5 times 
with distilled water to remove adsorbed ubiquitin and then filtered. The powder 
was dried under air at 37 °C for 12 hours. These samples were used as a control 
to determine the amount of ubiquitin incorporated into the particles.  
Ubiquitin-calcium phosphate prepared by the co-precipitation method (I) and 
calcium phosphate without ubiquitin (II) were analyzed by X-ray diffraction 
(XRD), infrared spectroscopy (IR), energy-dispersive X-ray analysis (EDX) and 
scanning electron microscopy (SEM). 
The percentage of radioactive ubiquitin incorporated into the calcium phosphate 
materials in co-precipitated samples (I) and control samples (III) was measured 
with a γ-counter (65 Gamma Counter 1480 WizardTM 3 '', Wallac). 
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5 Summary 
In this work chemical, biological and biochemical investigations were carried 
out in the cooperation with the Chair of Molecular Neurobiochemistry at the 
University of Bochum and with the Institute of Physico-Chemical Biology, 
Moscow State University. In this cooperation the main purpose was to find 
optimal conditions for the preparation of stable monodisperse calcium phosphate 
colloids and their applications in biological investigations on living cells. This 
interdisciplinary cooperation was necessary to understand major barriers in the 
gene delivery system and to develop a new system which can overcome these 
barriers or at least improve the trafficking of nucleic acids into the cells. 
We have demonstrated how by a comparatively easy and well reproducible 
process nanodisperse calcium phosphate/DNA nanoparticles with a size below 
100 nm can be prepared, especially if calcium is partially substituted by 
magnesium or aluminum. These ions obviously have an inhibitory effect on the 
particle growth of calcium phosphate.  
Multi-shell calcium phosphate/DNA-nanoparticles with a calcium phosphate 
core and DNA/calcium phosphate shells help to protect DNA from the 
degradation by enzymes (nucleases) inside the cytoplasm of cultured endothelial 
cells, reaching the efficiency of Polyfect®. 
Calcium phosphates should be advantageous due to their high biocompatibility 
and good biodegradability compared to other types of nanoparticles used for cell 
transfection such as iron oxide (magnetite), gold or silica. In contrast to the 
classical calcium phosphate method, the particle/DNA dispersions can be stored 
for weeks without loss of their transfection efficiency. 
We have developed a delivery system for gene silencing in which these 
nanoparticles are used for down-regulation of gene expression by targeting the 
mRNA resulting in effective gene silencing. The preparation of stable calcium 
Viktoriya Sokolova, Dissertation 2006 
 141
phosphate/oligonucleotide dispersions and their successful biological application 
in vitro to HeLa-EGFP cells was shown.  
The most challenging work in non-viral gene therapy is a successful delivery of 
DNA into the nuclei overcoming all the extracellular and intracellular physico-
chemical barriers. 
To get information about the targeting of calcium phosphate nanoparticles into 
T-HUVEC, fluorescence microscopy was used. The routing of nanoparticles 
inside the cells was studied. It was shown that the transfection efficiency 
correlates with the distribution of the nanoparticles in the cells. DNA/BSA 
aggregates alone were not able to penetrate the cell membrane, i.e. the inorganic 
nanoparticles (calcium phosphate) were necessary as carriers to enter the cell. 
We also performed the preparation of calcium phosphate samples with ubiquitin 
by the co-precipitation method. It was shown that ubiquitin can be adsorbed as 
well as incorporated into the calcium phosphate particles. This method shows 
opportunities in the preparation of calcium phosphate ceramics with proteins 
similar to ubiquitin, i.e. proteins of the BMP family. An implantation of such 
biofunctionalized calcium phosphate ceramics (e.g. cold-isostatically pressed 
into an appropriate shape) in bone defects can stimulate the development of new 
bone at the implantation site. 
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7 Appendix 
 
7.1 List of abbreviations 
 
A adenine 
ACP amorphous calcium phosphate 
Amp ampicillin 
ATCC american type cell culture collection 
Bp base pair 
BSA bovine serum albumin 
C cytosine 
CMV cytomegalovirus 
DCPD dicalcium phosphate dihydrate 
DEAE diethylaminoethyldextran 
DESY Deutsches Elektronen Synchrotron 
DLS dynamic light scattering 
DMEM Dulbeccos modified Eagles medium 
DNA deoxyribonucleic acid 
ds double stranded 
E. coli Escherichia coli 
EDTA ethylenediaminetetraacetate 
EDX energy dispersive X-ray analysis 
EGFP enhanced green fluorescent protein 
FCS fetal calf serum 
G guanine 
HA hydroxyapatite 
HASYLAB Hamburger Synchrotronstrahlungslabor 
HBS Hanks buffered saline 
HEPES 4-2-hydroxyethyl-1-piperazineethanesulfonic acid 
HIV human immune deficiency virus 
ICDD International Centre for Diffraction Data  
kDa kilodalton 
LB Luria Bertani 
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mRNA messenger RNA 
MTT methyl thiazole tetrazolium bromide 
NLS nuclear localisation sequence 
nm nanometre 
OD optic density 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
RISC RNA induced silencing complex 
RNA ribonucleic acid 
RNAi RNA interference 
rRNA ribosomal RNA 
SDS sodium dodecyl sulfate 
SV40 Simian virus 40 
SEM scanning electron microscopy 
siRNA small interfering RNA 
TEB tris-EDTA boric acid 
T-HUVEC transformed human umbilical vein endothelial cells 
TRITC trimethylrhodaminisothiocyanate 
TEM transmission electron microscopy 
TCP tricalcium phosphate 
tRNA transfer RNA 
UV ultraviolet 
XRD x-ray (powder) diffractometry 
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7.2 Safety and disposal of chemicals  
All chemical compounds used in experiments for this work are listed below. The 
column “symbol” lists the international hazard symbols appropriate for the 
specific compounds. R-Phrase and S-Phrase are listings of dangers and safety 
precautions required by German law. 
 
compound 
 
symbol R-Phrase S-Phrase disposal
AlCl3 Xi 34 26-36/37/39-45 2 
[CH3CH(OH)COO]2Ca -- -- -- 2 
Ca(NO3)2·4 H2O O, Xi 8-36 - 2 
CaCl2·2 H2O Xi 36 22-24 2 
Ethanol F 11 7-16 1 
HCl (37 % in H2O) C 34-37 26-36/37/39-45 4 
HNO3 (65 % in H2O) C, O 35 23-26-36/37/39-
45 
4 
KCl -- -- -- 2 
Mg(NO3)2·4 H2O Xi 8-36/37/38 17-26-36 2 
NaCl -- -- -- 2 
Na2CO3 -- -- -- 2 
Na2HPO4 -- -- -- 2 
NaH2PO4·2 H2O -- -- -- 2 
NaOH C 35 26-37/39-45 5 
(NH4)2HPO4 -- -- -- 2 
 
Disposal: 
1: organic solvents were disposed in the organic solvents disposal container 
for non-halogenated solvents  
2: solid were disposed in the container for solid waste 
3: inorganic compounds were made acidic, dissolved in water, and 
transferred to the container for acidic heavy metal solutions 
4: acids were transferred in to the container for heavy metal solutions 
5: bases were neutralised and transferred into waste water 
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2. V. Sokolova, I. Radtke, R. Heumann, M. Epple, "Effective transfection of 
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with custom-made calcium phosphate nanoparticles" (poster) 
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